ACKR3 modulators for cardiovascular or antiplatelet therapy

Abstract

The present invention discloses a compound of any of the general formulas (la) to (Ig): pharmaceutical compositions comprising said compounds and their use in the treatment of diseases, especially a disease is mediated by ACKR3, preferably a cardiovascular disease or a platelet disorder. In addition, method for treating a disease in which mediation, such as inhibition, regulation and / or modulation, of ACKR3 is beneficial in a human or a warm-blooded or mammal animal in need of such treatment is disclosed.

Description

ACKR3 modulators for cardiovascular or antiplatelet therapy

[0001] The invention relates to a novel compound for the treatment and prophy- laxis of a disease, especially a disease that is mediated by ACKR3, including but not lim- ited to a cardiovascular disease or a platelet disorder, a pharmaceutical composition com- prising said compound, and to a method for the treatment and / or prophylaxis of a disease, preferably a cardiovascular disease or a platelet disorder.FIELD OF THE INVENTION

[0002] The invention relates to the field of pharmaceutically active compounds, more particularly to the field of compounds useful in the treatment and prevention of con- ditions affecting the heart or blood vessels or in the treatment and prevention of abnormal clotting of platelets.BACKGROUND OF THE INVENTION

[0003] Chemokines, also known as chemotactic cytokines, are a family of sig- naling proteins, which primarily induce cell migration. Their involvement is prominent in several types of cell movement processes, for example, chemotaxis, haptotaxis, chemo- kinesis, haptokinesis, and transcellular migration. In addition to their function as chemoat- tractants, they take part in a variety of important processes like the homeostasis and de- velopment of the immune system or inflammatory signaling. Over 50 human chemokines have been identified, which are classified into four subfamilies (C, CC, CXC, CX3C). Their respective chemokine receptors can be divided into two families, the conventional chemo- kine receptors (cCKRs) and the atypical chemokine receptors (ACKRs). While all chemo- kine receptors are structurally homologous to GPCRs and therefore belong to the large family of G protein-coupled receptors, only the members of the cCKRs transduce signals through G-proteins. ACKRs engage in different transducers and functions, for example in the case of the atypical chemokine receptor 3 (ACKR3) by recruitment of beta-arrestin.

[0004] Due to their key roles in important physiological processes, efforts have been made to develop ligands for various chemokine receptors. With Maraviroc as the first C-C chemokine receptor type 5 antagonist in HIV treatment therapy and Plerixaflor, a C-X-C chemokine receptor type 4 (CXCR4) antagonist initially developed for HIV treat- ment, being used in some cancer patients before radiation or chemotherapy to mobilize stem cells into the bloodstream, the chemokine receptors were proven as viable drug tar- gets. ACKR3, formerly known as C-X-C chemokine receptor type 7 (CXCR7), is associ- ated with multiple diseases. It is expressed in a range of regions, among other things in the central nervous system, the adrenal gland, endothelial cells, immune cells, and plate- lets. Particularly, ACKR3’s importance in cardiovascular diseases (CVD) was discussed frequently in the recent scientific literature. As of today, cardiovascular diseases are the leading cause of death worldwide with approximately 17.9 million deaths per year. There- fore, new therapeutic strategies are in high demand. Several studies showed chemokines and ACKR3 play key roles in the process of CVD development, including upregulated ex- pression of ACKR3 in mice or humans suffering from atherosclerosis, strokes, myocardial infarction, and platelet function (Gawaz, M. et al. Current concepts and novel targets for antiplatelet therapy. Nature Reviews Cardiology 2023, 20, 583-599).

[0005] The enhanced surface expression of ACKR3 and its endogenous ligand stromal cell-derived factor-1 (SDF-1), also known as CXCL12, on platelets of patients with acute coronary syndrome was described. The role of ACKR3 in prothrombotic events was shown and substantiated later when all-cause mortality in patients with coronary artery disease (CAD) was associated with base-line levels of ACKR3 and C-X-C chemokine re- ceptor type 4 (CXCR4). While CXCR4 ligation by CXCL12 leads to Gi-mediated platelet activation, the opposite occurs when activating ACKR3. ACKR3 ligation promotes platelet survival, and inhibits platelet activation / aggregation and thrombus formation.

[0006] In Bayrak, A. et al., the first-in-class ACKR3 agonists for the modulation of platelet aggregation and degranulation are developed. Hereby, it was possible to prove, that ACKR3 ligation leads to the inhibition of platelet aggregation (Bayrak, A. et al. Discov- ery and development of first-in-class ACKR3 / CXCR7 superagonists for platelet degranula- tion modulation. J. Med. Chem. 2022, 65, 13365-13384).

[0007] An objective underlying the present invention is to provide compounds that are effective in inhibiting, regulating, and / or modulating ACKR3. Another objective is to provide compounds with one or more greatly improved potency, functional activity, and selectivity toward ACKR3. Still, another objective is targeting ACKR3 with small mole- cules. A further objective resides in the provision of ACKR3 inhibitors, regulators, and / or modulators as a medicament. Still, a further objective resides in the provision of ACKR3 inhibitors, regulators, and / or modulators that are efficient for use in the treatment of a car- diovascular disease or a platelet disorder as well as other diseases. Another objective re- sides in the provision of such compounds or compositions comprising such compounds with low toxicity to humans and / or warm-blooded or mammal animals.SUMMARY OF THE INVENTION

[0008] The abovementioned objectives have been achieved by providing a compound of any of the general formulas (la) to (Ig):or a stereoisomer, enantiomer, tautomer, pro-drug, and / or a pharmaceutically acceptable salt thereof, whereinX1is selected from substituted or unsubstituted cyclyl, substituted or unsubstituted hetero- cyclyl, substituted or unsubstituted fused cyclyl, and substituted or unsubstituted fused heterocyclyl,X2is selected from -SCH2-, -CH2CH2-, and a bond,X3is selected from carbonyl, thiocarbonyl, and methylene,Y1is selected from H and methyl,Y2is selected from substituted or unsubstituted phenyl, substituted or unsubstituted ben- zyl, tert-butyl, and tert-butyloxycarbonyl,Y3is selected from H, substituted or unsubstituted C1-C5 alkyl, and C3-C5 cycloalkyl,Y4and Y5are O, or Y4is selected from H, and methyl, Y5is selected from substituted or unsubstituted benzyl, substituted or unsubstituted benzoyl, and linear or branched C1-C5 alkylcarboxylate,A and B are independently selected from substituted or unsubstituted heterocyclyl, and substituted or unsubstituted fused heterocyclyl,C is selected from substituted or unsubstituted cyclyl, and n is 0-2.

[0009] The term "cyclyl" as used herein encompasses saturated or at least par- tially unsaturated cyclic compound having, e.g., 3 to 8 C-atoms, such as 3 C-atoms, 4 C- atoms, 5 C-atoms, and 6 C-atoms, and 7 C-atoms, and 8 C-atoms. Cyclyl residues also encompass aryl residues, such as phenyl. The definition of cyclyl is likewise applicable to any group that includes a cyclyl group, such as phenoxy. The cyclyl group may be bound to the neighboring group, e.g., another cyclyl residue, via a carbon atom (C-bound). Cyclyl residues may be also present as fused cyclyl residues, in which two or more C-atoms, such as 2 C-atoms, of a first cyclyl residue can form part of a second cyclyl residue.

[0010] The term "heterocyclyl" as used herein designates cyclyl residues con- taining one to three heteroatoms that may be independently selected from S, O, and N. The heterocyclyl group may be bound to the neighboring group, e.g., another cyclyl resi- due, e.g., via a carbon atom (C-bound) or a nitrogen heteroatom (N-bound). The definition of heterocyclyl is likewise applicable to any group which includes a heterocyclyl group.Heterocyclyl residues may be also present as fused heterocyclyl residues, in which two or more atoms of a first heterocyclyl residue can form part of a second heterocyclyl or cyclyl residue. Heterocyclyl groups can include thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridi- nyl, pyrimidinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrochinoline, and in- doline.

[0011] A preferred heterocyclyl residue is thiophen-2-yl. The thiophen-2-yl may be unsubstituted or substituted with one or two substituents, preferably, one substituent, more preferably at position 5 of the thiophen-2-yl residue.

[0012] A more preferred heterocyclyl residue is (substituted or unsubstituted phenyl)thiophen-2-yl. The substituted or unsubstituted phenyl residue may be located at position 5 of the thiophen-2-yl-residue forming (unsubstituted or 5-substituted phenyl)-thio- phen-2-yl-residue.

[0013] Preferred examples of substituted phenyl residues include 4-hydroxy- phenyl, 2-halo-phenyl, 3-halo-phenyl, 4-halo-phenyl, 4-methyl-phenyl, 4-fert-butyl-phenyl, 4-methoxy-phenyl, and one of the before mentioned substituted phenyl residues having one additional preferred substituent, such as 3,4-dihalo-phenyl, such as 3,4-difluoro-phe- nyl.

[0014] Another more preferred heterocyclyl residue, which may form A of the compound lb, preferably R2of the compound lib, is substituted or unsubstituted 3,4-dihy- droisoquinolin-2(1 / 7)-yl, or substituted or unsubstituted piperidine-1 -yl (each connected via the N-atom to the compound lb). Examples of substituted 3,4-dihydroisoquinolin-2(1 / 7)-yl include 3,4-dihydroisoquinolin-2(1f / )-yl. Examples of substituted piperidine-1 -yl include a 4-(alkylcarbamoyl)piperidin-1-yl, wherein alkyl is linear or branched C1-C5 alkyl, such as fert-butyl.

[0015] The term "bond" as used herein describes a chemical bond, in particular, a covalent single bond, which is formed between two residues.

[0016] The term "alkyl" as used herein encompasses linear or branched carbon chains. Preferred alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, 2-butyl, iso-butyl, ferf-butyl, pentyl, 1 -methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, and 1 -ethylpropyl. The definition of alkyl is likewise applicable to any group which includes an alkyl group, such as alkoxy, or thioalkoxy.

[0017] The term “substituted”, or “substituent” as used herein may designate residues including H, alkyl, heteroalkyl, cyclyl, heterocyclyl, fused cyclyl, fused heterocy- clyl, and combinations thereof. In addition, the term “substituted” designates residues in- cluding halogen or halo, such as F, Cl, Br, I, modifications to carbons by introducing one or more heteroatoms, such as N, S or O, or a carboxylate function, a primary, secondary, or tertiary amine function, which is optionally further substituted, an O carrying a substitu- ent, a carboxylic group, which is optionally further substituted.

[0018] Preferably “substituted” designates alkyl, such as linear or branched C1- C5 alkyl, hydroxyl, alkoxy, such as linear or branched C1-C5 alkoxy, thiol, thioalkyl, such as linear or branched C1-C5 thioalkyl, halogen or halo, such as F, Cl, Br, I, nitro, amine, mono- or dialkylamine, wherein each alkyl residue is independently selected from linear or branched C1-C5 alkyl, alkyl-carboxamide, and cyclyl-carboxamide.

[0019] Preferred examples of substituted benzyl residues include 2-halo-benzyl, 3-halo-benzyl, 4-halo-benzyl, 3-nitro-benzyl, 4-methoxy-benzyl.

[0020] The molecular sizes of the present residues are selected such that the present compounds do not exhibit a steric hindrance that negatively affects or even im- pedes biological activity. Therefore, the overall molecular weight of a substituent may be about < 200 g / mol, such as about < 150 g / mol, or about < 100 g / mol.

[0021] The term "small molecule" as used herein may refer to compounds of the invention having a low molecular weight of about 1.000 g / mol or less, such as 900 g / mol to 300 g / mol, 800 g / mol to 350 g / mol, 700 g / mol to 400 g / mol, 600 g / mol to 450g / mol, or 650 g / mol to 500 g / mol. Small molecules have the advantage of a simpler struc- ture, which facilitates their synthesis. In addition, their low molecular weight lends more predictability to their pharmacokinetics and / or pharmacodynamics, which in turn may facil- itate dosing. Furthermore, the small molecules can be easily administered, e.g. orally, and / or they can pass through cell membranes to reach intracellular targets.

[0022] The term "the present compounds", "the compounds of the invention" or "the compounds of formula (I)" or any other formula and / or structure include the pharma- ceutically acceptable salts, pro-drugs, biologically active metabolites, solvates, and stere- oisomers thereof.

[0023] The pharmaceutically acceptable salts may be acid addition salts with pharmaceutically acceptable acids. Examples of suitable pharmaceutically acceptable or- ganic and inorganic acids are hydrochloric acid, hydrobromic acid, phosphoric acid, sulfu- ric acid, sulfamic acid, C1-C4-alkylsulfonic acids, such as methanesulfonic acid, cycloali- phatic sulfonic acids, such as S-(+)-10-camphor sulfonic acid, aromatic sulfonic acids, such as benzenesulfonic acid and toluenesulfonic acid, di- and tricarboxylic acids and hy- droxycarboxylic acids having 2 to 10 carbon atoms, such as oxalic acid, malonic acid, ma- leic acid, fumaric acid, lactic acid, tartaric acid, citric acid, glycolic acid, adipic acid, and benzoic acid. Further suitable pharmaceutically acceptable acids may be derived from, e.g., Remington: The Science and Practice of Pharmacy, 23rdedition, October 30, 2020, Adeboye Adejare.

[0024] The invention also includes any tautomeric, crystal, and polymorphic forms of the compounds, salts, and mixtures thereof.

[0025] The invention also includes solvates such as hydrates.

[0026] The compounds of the invention may contain one or more chiral centers and exist in different optically active forms such as enantiomers and diastereomers.

[0027] As used herein, the term "pro-drug" refers to an agent that is converted into the parent drug in vivo by some physiological chemical process. An example, without limitation, of a pro-drug would be a compound of the present invention in the form of an ester.

[0028] Pro-drugs have many useful properties. For example, a pro-drug may be more water soluble than the ultimate drug, thereby facilitating intravenous administration of the drug. A pro-drug may also have a higher level of oral bioavailability than the ulti- mate drug. After administration, the pro-drug is enzymatically or chemically cleaved to de- liver the ultimate drug in the blood or tissue. Suitable pro-drugs are known to the skilled person.

[0029] The compounds of the invention may mediate (i.e., inhibit, regulate, and / or modulate) ACKR3 and are therefore useful in therapy, particularly, in the treatment of diseases or conditions mediated at least in part by ACKR3. They may be particularly useful in treating a cardiovascular disease or a platelet disorder.

[0030] Exemplary, cardiovascular diseases include coronary artery diseases, such as angina pectoris and heart attack, stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, abnormal heart rhythms, congenital heart dis- ease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, throm- boembolic disease, venous thrombosis, and atherosclerosis. Exemplary platelet disorders comprise thrombocytosis, thrombocythemia, and thrombocytopenia, such as immune thrombocytopenia and thrombotic thrombocytopenic purpura, Bernard Soulier disease, Glanzmann’s thrombasthenia, Hermansky Pudlak syndrome, Jacobsen syndrome, Lowe syndrome, platelet release, and storage pool defects, thrombocytopenia with absent ra- dius (TAR) syndrome and thrombotic thrombocytopenic purpura (TTP).

[0031] The compounds of the invention can also be used for the treatment of other diseases and disorders modulated through ACKR3, such as treatment of distress dysfunction diseases or conditions, chronic or acute pain, cancers (breast, brain, lym-phoma), fibrosis (e.g. cardiac fibrosis), inflammatory or autoimmune diseases and condi- tions, conditions of excessive or abnormal vascularization (e.g. wound healing), stem cell differentiation and mobilization disorders, brain and neuronal dysfunctions (e.g. Alzhei- mer's disease, multiple sclerosis and demyelinating diseases), kidney dysfunction, renal dysfunction, preeclampsia and obesity.

[0032] According to a preferred embodiment, the compound has the formula (la) or (lb), whereinX1is substituted or unsubstituted heterocyclyl, preferably substituted or unsubstituted th io- phen-2-yl, more preferably, (substituted or unsubstituted phenyl)thiophen-2-yl,X2is a bond,X3is carbonyl,Y1is H,Y2is unsubstituted benzyl,Y3is selected from linear or branched C1-C4 alkyl, C2-C3 alkyl phenyl and C3-C4 cycloalkyl, preferably methyl, andA is selected from substituted or unsubstituted 1 -piperidinyl, substituted or unsubstituted 3,4-dihydroisoquinolin-2(1 / - / )-yl, and n is 1.

[0033] According to another preferred embodiment, the compound has any of the general formulas (Ila) to (He):R4is halogen, preferably F.

[0034] Alternatively, the compound has the general formula (Ila), wherein R1isone or two residues that are independently selected from a substitu- ent, wherein the substituent is optionally further substituted. Preferably, R6is one or two residues that are independently selected from the group consisting of H, substituted or un- substituted C1-C5 alkyl, halo, such as F, Cl, Br, I, an O carrying a substituent, such as OH, and a S carrying a substituent, such as SH, a carboxylic group, which is optionally further substituted. More preferably R6is one or two residues that are independently se- lected from the group consisting of H, unsubstituted alkyl, linear or branched unsubstituted alkyl, OH, O(alkyl), halo or dihalo, such as F, Cl, Br, I.

[0035] Alternatively, the compound has the general formula (lib), wherein R2is^6 jSindependently selected from a substituent, wherein the substitu- ent is optionally further substituted. Preferably, R6is independently selected from the group consisting of H, substituted or unsubstituted C1-C5 alkyl, substituted or unsubsti- tuted C3-C5 cyclyl, halo, such as F, Cl, Br, I, a carboxylate function, which is optionally further substituted, an O carrying a substituent. More preferably R6is independently se- lected from the group consisting of H, halo, such as F, Cl, Br, I, unsubstituted alkyl, unsub- stituted cyclyl, O(C1-C5 unsubstituted alkyl. Still more preferably R6, is independently se- lected from the group consisting of H, F, Cl, Br, unsubstituted alkyl, unsubstituted cyclyl, substituted or unsubstituted C1-C4 alkyl, linear or branched C1-C4 alkyl, unsubstituted cyclyl, C2-C3 alkyl phenyl; R6, at benzyl, is independently selected from the group consist- ing of H, Br, F, O(alkyl), NCO(substituted cyclyl).

[0036] According to still another preferred embodiment, the compound has the general formula (lid) or (He):wherein

[0037] According to a preferred embodiment, the compound has a 0-Arrestin recruitment EC50 of 0.5 pM or less, preferably 0.1 pM or less, and / or a P-Selectin expres- sion reduction of 71% or more, preferably 90% or more. The compound has a [3-Arrestin recruitment EC50 of 0.5 pM or less, such as about 0.45 pM or less, about 0.40 pM or less, about 0.35 pM or less, about 0.30 pM or less, about 0.25 pM or less, about 0.20 pM or less, or about 0.15 pM or less. Preferably, the compound has a P-Arrestin recruitment EC50 of 0.1 pM or less. The compound has a P-Selectin expression reduction of 71% or more, such as 72% or more, 73% or more, 74% or more, 75% or more, 80% or more, or 85% or more. Preferably, the compound has a P-Selectin expression reduction of 90% or more, such as 95% or more, 96% or more, or 97% to 100%. The P-Arrestin recruitment EC50 and / or the P-Selectin expression reduction can be measured according to the de- scription.

[0038] According to another preferred embodiment, a pharmaceutical composi- tion is provided that comprises the present compound or a pharmaceutically acceptable salt, pro-drug, biologically active metabolite, solvate, or stereoisomer thereof.

[0039] According to still another preferred embodiment, the pharmaceutical composition further comprises an inert carrier and / or one or more other therapeutic agents.

[0040] According to a preferred embodiment, a compound of the present inven- tion or a pharmaceutically acceptable salt, pro-drug, biologically active metabolite, solvate, or stereoisomer thereof, or the present composition, is provided for use in the treatment of a disease or disorder.

[0041] According to another preferred embodiment, the disease is mediated by ACKR3.

[0042] According to another embodiment of the invention the disease or disor- der is selected from the group consisting of pain, distress dysfunction diseases or condi- tions, cancers, inflammatory or autoimmune diseases and conditions, conditions of exces- sive or abnormal vascularization (e.g. wound healing and HIV infectivity), stem cell differ- entiation and mobilization disorders, brain and neuronal dysfunctions (e.g. Alzheimer's disease, multiple sclerosis and demyelinating diseases), kidney dysfunction, renal dys- function, preeclampsia and obesity in a subject.

[0043] According to still another preferred embodiment, the disease is a cardio- vascular disease or a platelet disorder.

[0044] According to a preferred embodiment, the cardiovascular disease is se- lected from coronary artery diseases, such as angina pectoris and heart attack, stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, ab- normal heart rhythms, congenital heart disease, valvular heart disease, carditis, aortic an- eurysms, peripheral artery disease, thromboembolic disease, venous thrombosis, and ath- erosclerosis and wherein the platelet disorder is selected from thrombocytosis, thrombo- cythemia, and thrombocytopenia, such as immune thrombocytopenia and thrombotic thrombocytopenic purpura, Bernard Soulier disease, Glanzmann's thrombasthenia, Her- mansky Pudlak syndrome, Jacobsen syndrome, Lowe syndrome, platelet release and storage pool defects, thrombocytopenia with absent radius (TAR) syndrome and throm- botic thrombocytopenic purpura (TTP).

[0045] According to another preferred embodiment, a method for treating a dis- ease is provided, in which mediation, such as activation or inhibition, regulation, and mod- ulation, of ACKR3 is beneficial in a human or a warm-blooded or mammal animal in need of such treatment, which comprises administering to said human or warm-blooded ormammal animal a therapeutically effective amount of the present compound, or a pharma- ceutically acceptable salt, pro-drug, biologically active metabolite, solvate or stereoisomer thereof, or the present composition.

[0046] According to still another preferred embodiment, the disease is a cardio- vascular disease or a platelet disorder.

[0047] According to a preferred embodiment, the cardiovascular disease is se- lected from coronary artery diseases, such as angina pectoris and heart attack, stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, ab- normal heart rhythms, congenital heart disease, valvular heart disease, carditis, aortic an- eurysms, peripheral artery disease, thromboembolic disease, venous thrombosis, and ath- erosclerosis and wherein the platelet disorder is selected from thrombocytosis, thrombo- cythemia, and thrombocytopenia, such as immune thrombocytopenia and thrombotic thrombocytopenic purpura, Bernard Soulier disease, Glanzmann’s thrombasthenia, Her- mansky Pudlak syndrome, Jacobsen syndrome, Lowe syndrome, platelet release and storage pool defects, thrombocytopenia with absent radius (TAR) syndrome and throm- botic thrombocytopenic purpura (TTP).

[0048] The present compounds may be customarily administered in the form of pharmaceutical compositions which comprise at least one compound according to the in- vention, optionally together with a carrier, such as a pharmaceutically acceptable excipient and, optionally, one or more other drugs, such as a drug that is suitable for treating or pre- venting a cardiovascular disease or a platelet disorder.

[0049] These compositions can, for example, be administered orally, rectally, transdermally, subcutaneously, intraperitoneally, intravenously, intramuscularly, or in- tranasally. Examples of suitable pharmaceutical compositions are solid medicinal forms, such as powders, granules, tablets, in particular film tablets, lozenges, sachets, cachets, sugar- coated tablets, capsules, such as hard gelatin capsules and soft gelatin capsules, or suppositories, semisolid medicinal forms, such as ointments, creams, hydrogels, pastes or plasters, and also liquid medicinal forms, such as solutions, emulsions, in particular oil-in-water emulsions, suspensions, for example, lotions, injection preparations, and infusion preparations. In addition, liposomes and / or microspheres may be also used.

[0050] When producing the compositions, the compounds according to the in- vention are optionally mixed or diluted with one or more carriers, such as pharmaceutically acceptable excipients. Carriers, such as pharmaceutically acceptable excipients, can be solid, semisolid, or liquid materials that serve as vehicles, carriers, or medium for the com- pound of the present invention.

[0051] Suitable carriers, such as pharmaceutically acceptable excipients, are known to the skilled person and may be readily derived from textbooks. Formulations of suitable carriers, such as pharmaceutically acceptable excipients, can comprise pharma- ceutically acceptable auxiliary substances, such as wetting agents; emulsifying and sus- pending agents; preservatives; antioxidants; anti-irritants; chelating agents; coating auxil- iaries; emulsion stabilizers; film formers; gel formers; odor masking agents; taste corri- gents; resins; hydrocolloids; solvents; solubilizers; neutralizing agents; diffusion accelera- tors; pigments; quaternary ammonium compounds; refatting and overfatting agents; raw materials for ointments, creams or oils; silicone derivatives; spreading auxiliaries; stabi- lizers; sterilants; suppository bases; tablet auxiliaries, such as binders, fillers, glidants, dis- integrants or coatings; propellants; drying agents; opacifiers; thickeners; waxes; plasticiz- ers and white mineral oils. Formulations of suitable carriers may be prepared according to, e.g., Fiedler, H.P., Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Ge- biete [Encyclopedia of auxiliary substances for pharmacy, cosmetics, and related fields], 5th edition, ECV-Editio-Cantor-Verlag, 2001.

[0052] The compounds of the invention can be administered at a unit dose within the range of 2.5 to 5000 mg / m2body area or 0.05 to 100 mg / kg of the human or an- imal, particularly a warm-blooded or mammal animal. A unit dose form can contain 0.1 to 250 mg of compound of the invention. The daily dose will be necessarily varied depending upon the host treated, the route of administration, any co-therapies, and the severity of the disorder.

[0053] The present compounds may also be suitable for combination with other therapeutic agents or drugs. The invention therefore further relates to a combination com- prising a compound of the invention with one or more further therapeutic agents, particu- larly, for use in treating a cardiovascular disease, a platelet disorder, a disease associated with a cardiovascular disease, or a disease associated with a platelet disorder. The com- bination therapies of the invention may be administered adjunctively. By adjunctive admin- istration is meant the coterminous or overlapping administration of each of the compo- nents in the form of separate pharmaceutical compositions or devices. This regime of therapeutic administration of two or more therapeutic agents is referred to generally by those skilled in the art and herein as adjunctive therapeutic administration; it is also known as add-on therapeutic administration. Any and all treatment regimes in which a patient re- ceives separate but coterminous or overlapping therapeutic administration of the com- pounds of the invention and at least one further therapeutic agent are within the scope of the current invention. In one embodiment of adjunctive therapeutic administration as de- scribed herein, a patient is typically stabilized on a therapeutic administration of one or more of the components for a period of time and then receives administration of another component.

[0054] The combination therapies of the invention may also be administered simultaneously or sequentially. By simultaneous administration is meant a treatment re- gime wherein the individual components are administered together, either in the form of a single pharmaceutical composition or device comprising or containing both components, or as separate compositions or devices, each comprising one of the components, admin- istered simultaneously. Such combinations of the separate individual components for a simultaneous combination may be provided in the form of a kit-of-parts.

[0055] Suitable agents for use in combination with the compounds of the inven- tions include for example: anticoagulants, such as apixaban, dabigatran, edoxaban, hepa- rin, rivaroxaban, warfarin, antiplatelet agents and agents for dual antiplatelet therapy (DAPT), such as acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticagrelor, angi- otensin-converting enzyme (ACE) inhibitors, such as benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, angiotensin II re- ceptor blockers (or inhibitors), such as azilsartan, candesartan, eprosartan, irbesartan,losartan, olmesartan, telmisartan, valsartan, angiotensin receptor-neprilysin inhibitors (AR- N Is), such as, sacubitril / valsartan, beta blockers, such as acebutolol, atenolol, betaxolol, bisoprolol / hydrochlorothiazide, bisoprolol, metoprolol, nadolol, propranolol, sotalol, com- bined alpha and beta-blockers, such as carvedilol, labetalol hydrochloride, calcium chan- nel blockers, such as amlodipine, diltiazem, felodipine, nifedipine, nimodipine, nisoldipine, verapamil, cholesterol-lowering medications, such as statins including atorvastatin, fluvas- tatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, nicotinic acids includ- ing niacine, cholesterol absorption inhibitor including ezetimibe, combination statin and cholesterol absorption inhibitors such as ezetimibe / simvastatin, digitalis preparations, such as digoxin, diuretics, such as acetazolamide, amiloride, bumetanide, chlorothiazide chlorthalidone, furosemide, hydro-chlorothiazide, indapamide, metalozone, spironolac- tone, torsemide, and vasodilators, such as isosorbide dinitrate, isosorbide mononitrate, hydralazine, nitroglycerin, minoxidil.DETAILED DESCRIPTION

[0056] Design of New Compounds. The gist of the invention resides in finding potent ACKR3 ligands and screening them for their functional activity on platelet modula- tion. Starting from a publication from Yoshikawa et al., wherein a set of compounds were derived from molecular docking studies and evaluated for their binding affinity towards ACKR3 (Yoshikawa, Y. et al. Optimized method of g-protein-coupled receptor homology modeling: Its application to the discovery of novel CXCR7 ligands. J. Med. Chem. 2013, 56, 4236-4251), small molecules with moderate to good biological activity in ACKR3 mod- els were shown. It was chosen to optimize one of the reported ligands to achieve lower ECso values and functional activity. For the optimization process, a systematic approach was chosen. At first, the rigid ring moiety of the reported ligand was removed to open upto a more flexible core structure (Fig. 1). The initial compound 1 showed already 5-fold im- proved potency on our beta-arrestin recruitment assays. The new hit molecule was sepa- rated into 3 core components: the head, the tail, and the connecting linker (Fig. 1).

[0057] Starting with the head component, each moiety was then derivatized and tested individually for its affinity towards ACKR3. Profound structure-activity relationship studies led to lead compound 27 (ECso = 0.069 pM; P-Selectin exp. red. = 77%), with ex- cellent fi-Arrestin recruitment potency, full-agonistic properties, and great platelet func- tional activity. Therefore, compound 27 was further evaluated for its metabolic stability, cell toxicity, and selectivity towards ACKR3.

[0058] Hereinafter, the rational design, development, and evaluation of novel ACKR3 agonists, with high potency, efficacy, and selectivity towards ACKR3 is described. In addition, they inherit excellent properties, like functional activity and low cell toxicity, to allow this new class of compounds to be employed in future in vivo studies.

[0059] Chemistry. The synthesis of the final compounds was achieved in a range of different routes, but a significant number of finals (compounds 1-32) could be synthesized using a modular 3 to 5-step synthesis (Scheme 1). Beginning with the in situ Finkelstein reaction and nucleophile substitution reaction of terf-butyl (3-bromopropyl)car- bamate and the respective alkyl benzylamine provided the boc-protected linker as a pre- cursor. While most alkyl benzylamines were commercially available, compound 20’s, 29’s, and 30’s precursor (compound 20c, 29c, and 30c) were synthesized by employing a nu- cleophile substitution reaction or a reductive amination first. After successful purification, the boc-protected linker was deprotected using 4 M HCI in 1 ,4-dioxane. If possible, the solid HCI-salt of the free amine was collected using suction filtration and washed to obtain the pure product, otherwise, the solvent was evaporated, and the intermediate was used without further purification. The amine could then be coupled with the appropriate carbox- ylic acid using HATU and DIPEA as a base to obtain the final compounds. Compound 35 was synthesized likewise (Scheme 2), starting with commercially available tetrahydroiso- quinoline. In the case of left-hand site substituted compounds (“head optimization”, Struc- ture A, table 1), multiple compounds were synthesized by applying an extra step. By syn-thesizing the bromothiophene derivative (compound 2) first, it was possible to employ Su- zuki-coupling reactions with the respective boronic acid (pinacol ester) to obtain a range of different “left-hand site” substituted derivatives (compounds 9-17, 31 , 32) in a short amount of time.

[0060] Scheme 1. Synthesis of compounds 1 -33a

[0061] aReagents and conditions: (a) methanamine, 1-(bromomethyl)-4-fluoro- benzene, CS2CO3, KI, acetone, rt, 72 h or benzaldehyde, respective amine, NaBHsCN, EtOH, rt, 16 h, 33%-38%; (b) tert-butyl (3-bromopropyl)carbamate, respective benzyla- mine, CS2CO3, KI, acetone, rt, 72 h, 39%-69%; (c) 4M HCI in 1 ,4-dioxane, rt, 1 h, 52%- 98%; (d) respective carboxylic acid, DIPEA, HATU, DMF, rt, 16 h, 7%-86%; (d) respective boronic acid (pinacol ester), K2CO3, XPhos Pd G4, water / 1 ,4-dioxane (1 :4), 100°C, 16 h, 18%-72%.

[0062] Similar to the synthesis described above (Scheme 1), compounds 33, 38, 40, 44, 45, and 49 could be obtained in a short one-step amide coupling reaction. Compound 33 was then further derivatized in two steps, boc-deprotection, and reductive amination, to compound 34.

[0063] While most compounds could be obtained as described in a straightfor- ward manner, the remaining compounds needed to be synthesized in multiple different steps due to their heterogenic molecular structures. Compound 37 was synthesized be- ginning with saponification of the / V-boc-protected piperidine carboxylic acid ethyl ester.Subsequently, an amide coupling reaction with the resulting carboxylic acid (37e) and fert- butyl amine gave the intermediate 37d. After the acquisition of the deprotected amine with the use of 4 M HCI in 1 ,4-dioxane, the compound was treated as described above: in situ Finkelstein reaction with nucleophile substitution, boc-deprotection, and final amide cou- pling to give compound 37.

[0064] Compound 39 was synthesized in 3 steps. At first, reductive amination with benzaldehyde and the boc-protected 3-methylpiperidine, afterwards boc-deprotection using HCI in 1 ,4-dioxane, and finally the amide coupling with the carboxylic acid.

[0065] While compounds 36, 41 , and 43 share similar structural elements, their synthesis was achieved in different routes. 36 and 41 were initially synthesized in an am- ide coupling reaction between acetal-protected amino benzaldehyde and 4-fluorobenzoic acid. After subsequent deprotection of the acetal to the aldehyde and reductive amination with either tert-butyl (3-(methylamino)propyl)carbamate or tert-butyl 1 ,4-diazepane-1 -car- boxylate the intermediates 36b and 41b could be generated. Deprotection of the / V-termi- nal boc-group and amide coupling yielded final compound 36 or 41. Conversely, 43 was synthesized in multiple steps, starting with 1-(bromomethyl)-3-nitrobenzene and employ- ing a Gabriel synthesis using the Ing-Manske procedure to create the desired amine (pre- cursor 42a). For easier handling, 4 M HCI in 1 ,4-dioxane was added to the product to pre- cipitate the HCI salt of the amine. The precursor was then coupled with 5-phenylthio- phene-2-carboxylic acid to give the compound 42. From there on, a reduction of the nitro group and a subsequent amide coupling led to compound 43.

[0066] The precursor 46a for compounds 46 and 47 was synthesized in a 2- step route. Nucleophile substitution of mono boc-protected piperazine and A / -(3-Bromo- propyl)phthalimide gave intermediate 46b. Hydrazinolysis in ethanol yielded the desired intermediate, which was either used in an amide coupling reaction to give compound 46 or in a reductive amination reaction to give compound 47. Similarly, compound 48 was gen- erated with a reductive amination reaction of precursor 48a and phenylthiazole carbalde- hyde using sodium triacetoxyborohydride and triethylamine in dichloroethane. The precur- sor was synthesized from the above-mentioned compound 37e, which was, in this case,coupled with benzylamine instead of tert-butyl amine as in the synthesis of compound 37.Subsequent deprotection gave the desired intermediate 48a.

[0067] Scheme 2. Synthesis of compounds 33-46a.

[0068] aReagents and conditions: (a) respective amine, DIPEA, HATU, DMF, rt,16 h, 9%-quant.; (b) 4M HCI in 1 ,4-dioxane, rt, 1 h, quant.; (c) benzaldehyde, NaBH(OAc)3, Et3N, DCE, rt, 16 h, 30%; (d) Pd / C 10%, H2, EtOH, rt, 16 h.

[0069] Scheme 3. Synthesis of compounds 47-49a.

[0070] aReagents and conditions: (a) respective amine, NaBH(OAc)3, AcOH orEt3N, THF or DCE, rt, 16 h, 7%-71 %; (b) amine, DIPEA, HATU, DMF, rt, 16 h, 46%.

[0071] Structure-Activity Relationship Studies of Initial Hit. Starting from the compound from Yoshikawa et al. (Fig. 1 ) (EC50 = 2.21 pM), it was chosen to create a more flexible core structure by deleting the A / -methylamide moiety from the thieno[3,2-c]quinolin “head” part. This now new liberated phenylthiophene compound, 1 (EC50 = 0.416 pM), im- proved the potency in (3-Arrestin recruitment assays by ~5 fold. However, efforts to change this moiety to different aromatic structures, 6-7, depleted the compound's fi-Arres- tin recruitment activity. Attempts to fuse the phenyl moiety with the five-membered het- eroaromat (compounds 3-5) reduced the activity as well, with 3 (EC50 = 0.775 pM) being the best of this set of molecules. Therefore, our efforts were focused on the derivatization of the phenylthiophene moiety. Sterically demanding substituents like (ferf-butyl)phenyl (10) and methoxyphenyl (11 ) diminished activity, while smaller substituents were often tol- erated. Interestingly, the difluoro compound 17 (EC50 = 0.758 pM) lowered activity, but some single fluorinated compounds, for example, compound 16, improved it. The mole- cules showed regiospecific preferences. Most prominently, meta substitution (16, EC50 = 0.267 pM), elevated the activity by a great amount. Summarizing our findings towards “head” optimization, as described above, suggests that the phenylthiophene moiety is highly conserved in the binding of ACKR3. Only small substituents, like fluor, were toler- ated. The elevated binding affinity suggests either an interaction with the fluorine in the binding pocket or that modulation of lipophilicity through fluorination may play a key role.

[0072] The right-hand side of the molecule, the “tail”, was approached in a simi- lar manner. In the beginning, the benzyl moiety was exchanged for more space-demand- ing motifs. This let to loss of agonistic activity, for example in compounds 36 (EC50 = 2.1 pM) and 37 (EC50 = 3.2 pM). Focusing on smaller changes similar to the “head” optimiza- tion, with substituents like p-methoxy (18), p-bromo (19), or p-fluoro (20). Again, the fluori- nation proved to be the best choice with the m-fluorobenzyl derivate (22) showing the same potency as its m-fluoro “head" counterpart. With lipophilicity being an important fac- tor, a sterically more demanding, but more lipophile dihydroisoquinolin derivate (35) was synthesized. Interestingly, this compound elevated the agonistic activity to be our most potent candidate so far (EC50 = 0.150 pM).

[0073] Next, the optimization process was focused on the methyl substitution of the tertiary amine. At first, the binding pockets' spatial breadth was challenged with thesynthesis of sterically demanding compounds 24 (EC50 = 0.709 pM) and 25 (EC50 = 0.630 pM). While both compounds were still in the nanomolar range, they reduced initial hit ac- tivity moderately. The next rational approach was to investigate the binding pocket’s space by elongating the alkyl chain of the tertiary amine. Ethylamine derivative 23 (EC50 = 0.111 pM) greatly improved potency and encouraged further elongation of the alky chain. While propylamine derivative 26 (EC50 = 0.111 pM) did not enhance activity, butylamine derivative 27 (EC50 = 0.069 pM) showed excellent potency in the lower nanomolar range. Hereby, the long nonpolar unsaturated alkyl chains further supported our hypothesis, that lipophilicity may play a key role in the structure-activity relationship.

[0074] On the contrary, rigidification of the “linker” section abolished the (3-Ar- restin recruitment potency of the compounds. For example, 43 (EC50 = 3.35 pM), with an aromatic linker part and a similar structure to 36 (EC50 = 2.1 pM), showed moderate to low agonistic activity. Non-aromatic cyclization approaches, like diazepane derivatives 40 (EC50 = 1.2 pM) and 41 (EC50 = 76 pM), likewise lowered the potency by at least 3-fold.

[0075] Other experiments, like changing the thiophene ring to the more polar thiazole (derivatives “Structure E”, table 1 ) led to the loss of agonistic activity. Derivatiza- tion of this scaffold of compounds resulted in a maximum EC50 of 1.5 pM with compound 48.

[0076] Shorter molecules were also synthesized, but not sufficient enough to be further characterized, for example 49 at 4.55 ji / M with a short linker chain and a fused ben- zothiophene core.

[0077] Efficacy of Derivatives. The endogenous ligand of ACKR3, CXCL12, was set at 100% efficacy in / 3-Arrestin recruitment assays to serve as the standard for the determination of each compound's efficacy. As shown in Table 1 , most of the tested com- pounds were found to be full agonists of ACKR3. Hit compound 1 already showed a good efficacy of 71% and was improved further alongside the optimization efforts for (3-Arrestin recruitment and platelet degranulation activity. Most changes were tolerated well and did not influence the efficacy of compounds. Notably, highly potent compounds like 16 (Emax=103%), 23 (Emax = 95%), or 26 (Emax= 96%) showed full-agonistic properties for ACKR3. With 82% efficacy, the lead compound 27 proved to be an ACKR3 full-agonist while dis- playing excellent (i-Arrestin recruitment potency in the lower nanomolar range.

[0078] Platelet Degranulation Studies of Derivatives. Concurrent with the [i-Ar- restin recruitment potency optimization, the compounds were also tested and developed according to their functional activity. To determine the ability of a compound to modulate platelets, P-Selectin surface expression was measured. P-Selectin is a surface protein in- volved in cell adhesion mechanisms and can be found on activated platelets. After induc- tion of platelet aggregation in platelet-rich plasma (PRP), treatment with the respective compound should therefore lead to a significant reduction in P-Selectin expression. Fluo- rochrome-conjugated antibodies against P-Selectin were used to determine P-Selectin concentration compared to untreated PRP. The initial hit compound 1 (P-Selectin expres- sion reduction = 71 %) proved to be a potent platelet degranulation inhibitor. Although structural changes of the “head” moiety (Structure A, Table 1 ) of 1 improved the com- pound’s fi-Arrestin recruitment activity, functional activity was preserved, and in some cases even upgraded to nearly 100% P-Selectin expression reduction. Especially, com- pounds 16 and 31 showed high platelet activity while being up to 1.5-fold more potent than 1. Only compound 5 of the tested compounds from the “head’’-scaffold were inactive in terms of functional activity. Otherwise, the compounds showed resistance against changes in the left-hand side of the molecule. On the contrary, changes in the “tail” com- partment, showed a major influence in terms of platelet modulation activity. Further rigidi- zation, like compound 35, led to decreased functional activity, while substitution of the benzyl moiety in the para-position seemed to enhance P-Selectin expression reduction. Compound 20 (ECso = 0.370 pM; P-Selectin expression reduction = 86%), is the best mol- ecule of this group considering both fi-Arrestin recruitment and flow cytometry assays. In- terestingly, in contrast to 20’s para-fluorination, meta, and ortho fluorination decreased function activity in compounds 22 with 66% reduction and 21 with 40% reduction. Simi- larly, platelet degranulation potency was highly sensitive toward “linker”-changes (Struc- ture C, Table 1). A distinct trend could not be registered. With compounds 23, 26, and 27 as the most potent molecules in terms of ft-Arrestin recruitment, they proved to be potent platelet modulators as well. Compared to the commercially available reference compoundVUF11207 (P-Selectin expression reduction = 65%), most compounds showed superior functional activity.

[0079] Indeed, 27 showed excellent fi-Arrestin recruitment activity (ECso = 69 nM) and high P-selection expression reduction (77%) and was found to be the most inter- esting substance for further evaluations.

[0080] Table 1. Structure-activity relationship studies.jB-Arrestm re- ,p,3P-Selectin ex- cruitment ' "rvri 17 pression re-EC50(pM)aJZw duction (%)cStructure A: Head optimizationStructure B: Tail optimizationStructure C: Linker optimizationStructure E: Shortened Linker for structure see above 4.55 25 70 aAverage value of three independent experiments.bThe efficacy of CXCL12 at 300 nM was set as 100%; the average value of three independent experiments.CPRP was pre-in- cubated with compound (100 pM) and then treated with CRP-XL (1 pg / mL). Data are ex- pressed as a percentage of P-Selectin-MFI (% ±SEM) normalized to CRP-XL-treated ve- hicle PRP (DMSO 0.1 %) from at least three individual experiments in duplicate. Dash (-) = Not tested.

[0081] Selectivity studies. To evaluate the selectivity of chosen most promising compounds, the compounds were tested against a variety of receptors, ACKR2, CXCR3, and CXCR4. Especially, CXCR4 selectivity was desired, since its activation often led to opposite physiological effects compared to ACKR3.

[0082] All compounds showed high selectivity against stated receptors. Their potency for these receptors was over the measuring limit of our assay and determined higher than 10 pM for all tested compounds as shown in Table 2 and Fig. 2.

[0083] Table 2: selectivity studies5 0.150 > 10 > 10 > 10aAverage value of three independent experiments (pM).

[0084] Cell viability studies. For further evaluations, the compounds 23 and 27, were tested in cell viability assays to determine their toxicity. In HEK293 cells, both com- pounds showed superior qualities compared to VUF11207 in terms of cell toxicity. Both tested compounds were tolerated well by the HEK293 cells in concentrations of 1 pM and below. Even longer testing periods of up to 72 h showed no influence on the cells during compound treatment (Fig. 5).

[0085] Platelet aggregation studies. To further evaluate the compounds inhibi- tory potential of platelet aggregation, aggregation experiments were conducted. All tested compounds, including reference compound VUF11207, showed a reduction of platelet ag- gregation compared to the control. Notably, compound 23 showed the highest potency for platelet aggregation inhibition. Combined with its excellent potency in FACS experiments, compound 23 shows great potential as a tool compound as shown in Fig. 3.

[0086] Metabolic stability studies. As shown in Fig. 4, compound 27 was stable in human liver microsomes over the course of 60 min. Around 69% of compound 27 re- mained, while the rest was determined to be a mixture of different metabolites. The most prominent metabolite was identified to be the de-benzylated compounds, while the dealkylation of the A / -butyl chain took second place in terms of metabolite quantity. Subse- quently, the metabolism of the compound further using mouse liver microsomes was stud- ied. The substance showed weaker stability properties and remained in quantities around 24% after 60 min in this assay. Concluding, while the compound has already great char-acteristics in terms of human metabolic activity, it requires further optimization efforts to- ward mouse liver microsome stability. In addition, in vitro metabolic stability studies of compounds 1 , 12, 23, 29, and 30 in mouse liver microsomes are shown (Fig. 6).

[0087] Solubility studies: The solubility of compounds 26, 30 has been tested (Table 3). Both compounds show good solubility in a mixture 1 vol.% DMSO and 99 vol.% PBS buffer.

[0088] Table 3. Kinetic solubility studies of selected compounds.Compound Structure Solubility [pM]aSolubility [mg / ml]aaAverage value of three independent experiments (pM ± SEM). The compound was solved in 1% DMSO, mixed with 99% PBS buffer (pH 7.4), then centrifuged at 16,000 g for 20 min. Solubility was determined in comparison to a standard curve of the respective compound.

[0089] It is to be understood that the before-mentioned features and those to be mentioned in the following cannot only be used in the combination indicated in the respec- tive case, but also in other combinations or in an isolated manner without departing from the scope of the invention.

[0090] The invention is now further explained by means of embodiments result- ing in additional features, characteristics, and advantages of the invention. The embodi- ments are of pure illustrative nature and do not limit the scope or range of the invention. The features mentioned in the specific embodiments are general features of the invention which are not only applicable in the specific embodiment but also in an isolated manner and in the context of any embodiment of the invention.

[0091] The invention is now described and explained in further detail by refer- ring to the following non-limiting examples and figures.BRIEF DESCRIPTION OF THE FIGURES

[0092] Fig. 1 shows the optimization process starting with the compound devel- oped by Yoshikawa Y. et al.

[0093] Fig. 2 shows P-Arrestin recruitment activity of selected most potent com- pounds against CXCR4.

[0094] Fig. 3 shows the aggregation of platelets after preincubation with 100 pM ACKR3 agonist and subsequent activation with 2.5 pM ADP.

[0095] Fig. 4 shows in vitro metabolic stability studies of lead compound 27 in human liver microsomes.

[0096] Fig. 5 shows cell viability assays of compounds 23 and 27 in comparison to reference compound VUF11207 over 1 h, 24 h, 48 h, and 72h.

[0097] Fig. 6 shows in vitro metabolic stability studies of compounds 1 , 16, 26, 27, and 35 in mouse liver microsomes.EXAMPLES

[0098] Chemistry and Methods.

[0099] Starting materials, reagents, and (anhydrous) solvents were commer- cially available and purchased from a range of manufacturers and used without further pu- rification. Thin-layer chromatography (TLC) with Macherey-Nagel precoated 60 F254 silica plates was used for reaction controls. TLC-Spots were visualized either by ultraviolet (UV)light (254 nm / 365 nm) or staining solutions. For purification purposes, flash column chro- matography was carried out using Grace Davison Davisil LC60A (20-45 jum) or Merck Geduran Si60 (mesh 63-200 pm) using a LaFlash (VWR International GmbH, Darmstadt, Germany) automated flash chromatography system. NMR spectra were recorded on a Broker Avance 400 MHz spectrometer at ambient temperature. Chemical shifts (5) are re- ported in parts per million (ppm) relative to the internal control tetramethylsilane (TMS), and the spectra were calibrated against the residual solvent peak of the used deuterated solvent (either DMSO-d6 or CDCh). Coupling constants (J) are expressed in hertz (Hz). The purity of all compounds was determined by RP-HPLC using an Agilent 1100 Series LC with a Phenomenex Luna C8 analytical column (150 x 4.6 mm, 5 pm) and detected by a UV DAD detector at 254 nm and 230 nm wavelength. Elution was carried out with the following gradient: [A = 0.01 M KH2PO4, pH 2.30, B = MeOH] 40% B to 85% B in 8 min, 85% B for 5 min, 85% to 40% B in 1 min, 40% B for 2 min, stop time 16 min, flow 1 .5 mL / min. Mass spectra analysis were obtained from an Advion expression compact mass spectrometer (electrospray ionization, ESI) with a TLC plate reader system (using the fol- lowing settings: ESI voltage 3.50 kV, capillary voltage 187 V, source voltage 44 V, capil- lary temperature 250 °C, desolvation gas temperature 250 °C, gas flow 5 L / min). High-res- olution mass spectra (HRMS) were determined for final compounds by the mass spec- trometry department, Institute of Organic Chemistry, Eberhard Karls University Tubingen on a Bruker maXis 4G ESI-TOF (Broker Daltonik GmbH, Bremen, Germany). The instru- ment was operated in ESI positive mode, and settings were as follows: nebulizer gas 1.2 bar, gas flow 6.0 L / min, source temperature 200 °C, capillary voltage +4500 V, end plate offset -500 V. The m / z range was from 80 to 1050 m / z. All final compounds are >95% pure determined by above mentioned HPLC procedure. Compound NMR spectra are ac- cessible in the SI Pages S26-S68. Synthesis of precursors are available in SI Pages S4- S25.

[0100] Synthesis. General Procedure I: Amide Coupling. The carboxylic acid was dissolved in dry DMF (2.5 mL) and HATU (1.2 eq.) was slowly added to the solution. After 15 min of continuous stirring, amine (1 eq.) and DIPEA (3 eq.) were added to the mixture. The mixture was allowed to stir at room temperature overnight. After complete re- action, the mixture was diluted with DCM (10 mL) and washed with water (3x 10 mL) andbrine (3x 10 mL). The combined organic phases were dried over anhydrous Na2SO4, fil- tered, and evaporated to dryness. The crude product was purified via flash chromatog- raphy or suction filtration.

[0101] General Procedure II: Suzuki Coupling. To a vial containing the organo- halide, the boronic acid or boronic acid pinacol ester (1.1 eq.), XPhos Pd G4 (0.05 eq.), and K2CO3 (3 eq.) were added 1 ,4-dioxane (2 mL) and water (0.5 mL). The mixture was degassed with argon and heated to 100 °C for 16 h. After complete reaction, the mixture was diluted with EtOAc (10 mL) and washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and evapo- rated to dryness. The crude product was purified via flash chromatography (SiCk; DCM / MeOH).

[0102] General Procedure III: Reductive Amination. The carbaldehyde (1.1 eq.) was dissolved in THF or DCE (5 mL) and one drop of acetic acid or triethylamine was added to the solution. After 15 min of continuous stirring, the amine was added, and the mixture was allowed to stir for 1 h. The mixture was cooled to 0 °C and sodium triacetoxy- borohydride (1.5 eq.) was added. After complete reaction, the mixture was diluted with EtOAc (10 mL) and washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phases were dried over anhydrous Na2SO4, filtered, and evaporated to dryness. The crude product was purified via flash chromatography (SiO2j DCM / MeOH).

[0103] N-(3-(benzyl(methyl)amino)propyl)-5-phenylthiophene-2-carboxamide (1). Prepared from 5-phenylthiophene-2-carboxylic acid (0.84 mmol) and A / 1-benzyl-A / 1- methylpropane-1 ,3-diamine dihydrochloride (1a, 0.84 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (2-7%). Yield: 150 mg (49%), yellow semi-solid.1H NMR (400 MHz, CDCI3) δ 8.02 (s, 1 H), 7.59 (d, J = 7.2 Hz, 2H), 7.46 - 7.28 (m, 9H), 7.21 (d, J = 3.9 Hz, 1 H), 3.74 (s, 2H), 3.56 (q, J = 11 .4, 5.5 Hz, 2H), 2.80 (t, 2H), 2.42 (s, 3H), 1.92 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 162.84, 149.07, 137.46, 135.50, 133.70, 130.00, 129.48, 129.17, 128.95, 128.61 , 128.43, 126.22, 123.72, 62.68, 56.20, 40.74, 39.30, 25.16. TLC-MS (ESI+): calcd. m / z 364.16 for C20H24N2OS. Found 365.2 [M+H]+. HPLC fR= 5.778 min.

[0104] N-(3-(benzyl(methyl)amino)propyl)-5-bromothiophene-2-carboxamide (2). Prepared from 5-bromothiophene-2-carboxylic acid (1.04 mmol) and A / 1-benzyl- / V1- methylpropane-1 ,3-diamine dihydrochloride (1a, 1.04 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (3-7%). Yield: 235 mg (53%), pale brown solid.1H NMR (400 MHz, CDCI3) δ 8.24 (s, 1 H), 7.36 - 7.26 (m, 5H), 6.93 (dd, J = 12.9, 3.9 Hz, 2H), 3.54 (s, 2H), 3.50 (q, J = 10.4, 4.1 Hz, 2H), 2.61 (t, 2H), 2.27 (s, 3H), 1.78 (quint, J = 11.6, 5.8 Hz, 2H).13C NMR (101 MHz, CDCI3) δ 160.85, 141.21 , 138.02, 130.58, 129.62, 128.62, 127.84, 127.68, 117.28, 63.37, 57.37, 50.97, 41 .62, 40.66, 25.05. TLC-MS (ESI+): calcd. m / z 366.04 / 369.04 for Ci6Hi9BrN2OS. Found 367.1 / 369.2 [M+H]+. HPLC fa = 4.709 min.

[0105] N-(3-(benzyl(methyl)amino)propyl)benzo[b]thiophene-2-carboxamide (3). Prepared from benzo[b]thiophene-2-carboxylic acid (0.6 mmol) and Af-benzyl-A / 1- methylpropane-1 ,3-diamine dihydrochloride (1a, 0.6 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (2-5%). Yield: 73 mg (36%), yellow solid.1H NMR (400 MHz, CDCI3) δ 8.41 (t, 1 H), 7.82 (d, J = 7.6 Hz, 1 H), 7.71 (d, J = 7.3 Hz, 1 H), 7.60 (s, 1 H), 7.44 - 7.33 (m, 4H), 7.34 - 7.27 (m, 3H), 3.70 (s, 2H), 3.58 (q, J = 10.9, 5.3 Hz, 2H), 2.77 (t, J = 5.7 Hz, 2H), 2.39 (s, 3H), 1.91 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 162.7, 141.0, 139.4, 139.1 , 130.0, 128.8, 128.2, 126.2, 125.2, 125.1 , 124.8, 122.7, 62.8, 56.5, 41.0, 39.9, 25.0. TLC-MS (ESI+): calcd. m / z 338.15 for C20H22N2OS. Found 339.2 [M+H]+. HPLC fa = 4.067 min.

[0106] N-(3-(benzyl(methyl)amino)propyl)-1H-indole-2-carboxamide (4). Pre- pared from 1H-indole-2-carboxylic acid (0.84 mmol) and A / 1-benzyl-A / 1-methylpropane-1 ,3- diamine dihydrochloride (1a, 0.84 mmol, 1 eq.) according to general procedure 1. Purifica- tion by flash chromatography with DCM / MeOH (2-7%). Yield: 151 mg (56%), yellow solid.1H NMR (400 MHz, CDCI3) δ 9.73 (s, 1 H), 8.20 (t, 1 H), 7.47 (d, J = 8.0 Hz, 1 H), 7.37 (d, J = 8.2 Hz, 1 H), 7.32 - 7.22 (m, J = 14.0, 6.8, 3.5 Hz, 5H), 7.18 (td, J = 15.3, 0.9 Hz, 1 H), 7.04 (t, J = 7.5 Hz, 1 H), 6.55 (s, 1 H), 3.56 (s, 2H), 3.52 (q, J = 11 .3, 5.5 Hz, 2H), 2.73 - 2.55 (m, 2H), 2.26 (s, 3H), 1.78 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 162.14, 136.90, 136.49, 131.06, 129.86, 128.82, 128.03, 127.80, 124.34, 121.99, 120.54, 112.18, 102.62, 63.03, 56.85, 41.10, 39.65, 25.25. TLC-MS (ESI+): calcd. m / z 318.18 for C20H23N3O. Found 322.2 [M+H]+. HPLC fa = 1.089 min.

[0107] N-(3-(benzyl(methyl)amino)propyl)benzofuran-2-carboxamide (5). Pre- pared from benzofuran-2-carboxylic acid (0.16 mmol) and A / 1-benzyl- / V1-methylpropane- 1 ,3-diamine dihydrochloride (1a, 0.16 mmol, 1 eq.) according to general procedure 1. Pu- rification by flash chromatography with DCM / MeOH (0-4%). Yield: 15 mg (30%), yellow semi-solid.1H NMR (400 MHz, CDCI3) δ 8.23 (s, 1 H), 7.62 (d, J = 7.8 Hz, 1 H), 7.44 - 7.15 (m, 9H), 3.61 (s, 2H), 3.56 (q, J = 11 .2, 5.5 Hz, 2H), 2.64 (t, J = 5.9 Hz, 2H), 2.30 (s, 3H), 1.85 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 159.2, 154.9, 149.3, 129.6, 128.7, 127.8, 127.7, 126.7, 123.7, 122.7, 111.9, 110.0, 63.0, 56.4, 41.6, 39.2, 29.8, 25.7. TLC-MS (ESI+): calcd. m / z 322.17 for C20H22N2O2. Found 323.2 [M+H]+. HPLC fR= 4.123 min.

[0108] N-(3-(benzyl(methyl)amino)propyl)-4-fluorobenzamide (6). Prepared from 4-fluorobenzoic acid (0.33 mmol) and A / 1-benzyl-A / 1-methylpropane-1 ,3-diamine dihy- drochloride (1a, 0.33 mmol, 1 eq.) according to general procedure 1 . Purification by flash chromatography with DCM / MeOH (3-7%). Yield: 41 mg (41%), brown semi-solid.1H NMR (400 MHz, CDCI3) δ 8.17 (s, 1 H), 7.72 - 7.60 (m, J = 8.4, 5.5 Hz, 2H), 7.31 - 7.18 (m, J = 1 .8 Hz, 5H), 6.99 (t, J = 8.6 Hz, 2H), 3.63 - 3.46 (m, 4H), 2.64 (t, 2H), 2.26 (s, 3H), 1 .82 (quint, J = 11.4, 5.8 Hz, 2H).13C NMR (101 MHz, CDCI3) δ 166.29, 165.86, 163.37, 137.98, 130.90, 130.87, 129.53, 129.38, 129.29, 128.56, 127.60, 115.53, 115.32, 63.22, 57.21 , 41.53, 40.45, 25.25. TLC-MS (ESI+): calcd. m / z 300.16 for CI8H2IFN2O. Found 301.2 [M+H]+. HPLC fa = 3.618 min.

[0109] N-(3-(benzyl(methyl)amino)propyl)-2-(phenylthio)acetamide (7). Pre- pared from 2-(phenylthio)acetic acid (0.36 mmol) and A / 1-benzyl-A / 1-methylpropane-1,3- diamine dihydrochloride (1a, 0.36 mmol, 1 eq.) according to general procedure 1. Purifica- tion by flash chromatography with DCM / MeOH (1-4%). Yield: 28 mg (24%), yellow oil.1H NMR (400 MHz, CDCI3) δ 7.71 (s, 1 H), 7.32 - 7.13 (m, 10H), 3.59 (s, 2H), 3.41 (s, 2H), 3.30 (q, J = 12.1 , 5.9 Hz, 2H), 2.32 (t, J = 6.3 Hz, 2H), 2.09 (s, 3H), 1.60 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 167.87, 138.30, 135.31 , 129.32, 129.31, 128.43, 127.57, 127.34, 126.36, 62.85, 55.35, 41.93, 39.11 , 37.12, 26.03. TLC-MS (ESI+): calcd. m / z 328.16 for CI9H24N2OS. Found 329.2 [M+H]+. HPLC fa = 4.079 min.

[0110] N-(3-(benzyl(methyl)amino)propyl)-3-(2-fluorophenyl)propanamide (8). Prepared from 3-(2-fluorophenyl)propanoic acid (1.67 mmol) and A / 1-benzyl-A / 1-methylpro- pane-1 ,3-diamine dihydrochloride (1a, 1.67 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (2-6%). Yield: 470 mg (86%), brown semi-solid.1H NMR (400 MHz, CDCI3) δ 7.32 - 7.19 (m, 5H), 7.19 - 7.09 (m, 2H), 7.04 - 6.89 (m, 2H), 6.72 (t, 1 H), 3.47 (s, 2H), 3.25 (q, 2H), 2.91 (t, J = 7.7 Hz, 2H), 2.42 (t, J = 6.1 Hz, 2H), 2.36 (t, 2H), 2.17 (s, 3H), 1.61 (quint, 2H).13C NMR (101 MHz, CDCh) 5 172.28, 162.39, 159.96, 137.72, 130.87, 130.82, 129.31 , 128.61 , 128.10, 128.02, 127.87, 127.71 , 127.66, 124.19, 124.15, 115.40, 115.18, 62.61 , 55.41 , 41.51 , 38.57, 36.80, 25.68, 25.33, 25.31. TLC-MS (ESI+): calcd. m / z 328.20 for C20H25FN2O. Found 329. [M+H]+. HPLC fR= 4.507 min.

[0111] N-(3-(benzyl(methyl)amino)propyl)-5-(p-tolyl)thiophene-2-carboxamide (9). Prepared from A / -(3-(benzyl(methyl)amino)propyl)-5-bromothiophene-2-carboxamide (2, 0.22 mmol) and p-tolylboronic acid (0.24 mmol, 1.1 eq.) according to general proce- dure 2. Purification by flash chromatography with DCM / MeOH (4-8%). Yield: 30 mg (33%), brown semi-solid.1H NMR (400 MHz, CDCI3) δ 8.06 (s, 1 H), 7.35 (d, J = 7.2 Hz, 1 H), 7.29 - 7.20 (m, 9H), 6.92 (d, J = 3.8 Hz, 1 H), 3.56 - 3.48 (m, 4H), 2.58 (t, 2H), 2.39 (s, 3H), 2.27 (s, 3H), 1.78 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 161.93, 147.40,138.91 , 138.25, 136.17, 133.59, 130.98, 130.42, 129.56, 128.53, 128.51 , 128.02, 127.49,126.91 , 126.14, 63.30, 57.04, 41.82, 40.43, 25.43, 21.19. TLC-MS (ESI+): calcd. m / z 378.18 for C23H26N2OS. Found 379.2 [M+H]+. HPLC fR= 6.242 min.

[0112] N-(3-(benzyl(methyl)amino)propyl)-5-(4-(tert-butyl)phenyl)thiophene-2- carboxamide (10). Prepared from A / -(3-(benzyl(methyl)amino)propyl)-5-bromothiophene-2- carboxamide (2, 0.22 mmol) and (4-(ferf-butyl)phenyl)boronic acid (0.25 mmol, 1.1 eq.) according to general procedure 2. Purification by flash chromatography with DCM / MeOH (6-10%). Yield: 27 mg (26%), brown solid.1H NMR (400 MHz, CDCI3) δ 8.06 (t, 1 H), 7.43 (dd, J = 45.9, 8.4 Hz, 4H), 7.28 - 7.20 (m, 6H), 7.11 (d, J = 3.8 Hz, 1 H), 3.54 - 3.46 (m, 4H), 2.57 (t, J = 5.8 Hz, 2H), 2.25 (s, 3H), 1.76 (quint, 2H), 1.30 (s, 9H).13C NMR (101 MHz, CDCI3) δ 161.94, 151.72, 148.49, 138.17, 137.85, 131.05, 129.62, 128.86, 128.57, 127.53, 126.04, 125.91 , 122.99, 63.30, 57.10, 41.74, 40.45, 34.80, 31.35, 25.38. TLC-MS (ESI+): calcd. m / z 420.22 for C26H32N2OS. Found 421.2 [M+H]+. HPLC fe = 7.967 min.

[0113] N-(3-(benzyl(methyl)amino)propyl)-5-(4-methoxyphenyl)thiophene-2-car- boxamide (11). Prepared from / V-(3-(benzyl(methyl)amino)propyl)-5-bromothiophene-2- carboxamide (2, 0.19 mmol) and (4-methoxyphenyl)boronic acid (0.21 mmol, 1.1 eq.) ac- cording to general procedure 2. Purification by flash chromatography with DCM / MeOH (4- 8%). Yield: 57 mg (71%), yellow-brown solid.1H NMR (400 MHz, CDCI3) δ 7.95 (t, 1 H), 7.50 - 7.42 (m, 2H), 7.30 - 7.16 (m, J = 12.8, 7.9, 4.7 Hz, 6H), 7.01 (d, J = 3.8 Hz, 1 H), 6.90 - 6.82 (m, 2H), 3.78 (s, 3H), 3.53 - 3.45 (m, 4H), 2.55 (t, 2H), 2.23 (s, 3H), 1 .74 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 161.92, 159.98, 148.39, 138.33, 137.33, 129.57, 128.90, 128.53, 127.46, 126.65, 122.33, 114.51 , 63.32, 57.14, 55.48, 41.76, 40.40, 25.50. TLC-MS (ESI+): calcd. m / z 394.17 for C23H26N2O2S. Found 395. [M+H]+. HPLC fa = 5.547 min.

[0114] N-(3-(benzyl(methyl)amino)propyl)-5-(4-hydroxyphenyl)thiophene-2-car- boxamide (12). Prepared from A / -(3-(benzyl(methyl)amino)propyl)-5-bromothiophene-2- carboxamide (2, 0.21 mmol) and (4-hydroxyphenyl)boronic acid (0.23 mmol, 1.1 eq.) ac- cording to general procedure 2. Purification by flash chromatography with DCM / MeOH (5- 8%). Yield: 21 mg (24%), brown solid.1H NMR (400 MHz, CDCI3) δ 8.14 (s, 1 H), 7.37 (d, J = 10.8 Hz, 2H), 7.28 - 7.17 (m, J = 7.6, 3.5 Hz, 6H), 6.99 (d, J = 3.8 Hz, 1 H), 6.87 (d, J = 8.4 Hz, 2H), 6.36 (s, 1 H), 3.56 (s, 2H), 3.51 (q, J = 4.5 Hz, 2H), 2.61 (t, J = 5.8 Hz, 2H), 2.27 (s, 3H), 1.80 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 162.56, 157.58, 149.40, 137.31 , 136.10, 129.83, 129.49, 128.65, 127.78, 127.63, 125.63, 122.15, 116.30, 63.03, 56.80, 41.50, 40.39, 25.22. TLC-MS (ESI+): calcd. m / z 380.16 for C22H24N2O2S. Found 381 .2 [M+H]+. HPLC fa = 4.041 min.

[0115] N-(3-(benzyl(methyl)amino)propyl)-5-(pyridin-4-yl)thiophene-2-carboxa- mide (13). Prepared from / V-(3-(benzyl(methyl)amino)propyl)-5-bromothiophene-2-carbox- amide (2, 0.27 mmol) and pyridin-4-ylboronic acid hydrate (0.3 mmol, 1.1 eq.) according to general procedure 2. Purification by flash chromatography with DCM / MeOH (5-8%). Yield: 36 mg (33%), yellow oil.1H NMR (400 MHz, CDCI3) δ 8.58 (d, J = 5.6 Hz, 2H), 8.35 (s, 1 H), 7.40 (d, J = 4.7, 1 .5 Hz, 2H), 7.30 (d, J = 4.5 Hz, 1 H), 7.28 - 7.23 (m, 5H), 7.21 (d, J = 3.9 Hz, 1 H), 3.57 - 3.49 (m, 4H), 2.61 (t, 2H), 2.25 (s, 3H), 1.78 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 161.25, 150.62, 144.61, 140.95, 140.83, 138.18, 129.67, 128.71,128.58, 127.59, 125.52, 120.06, 63.41, 57.56, 41.66, 40.82, 25.11. TLC-MS (ESI+): calcd. m / z 365.16 for C21H23N3OS. Found 366.2 [M+H]+. HPLC fa = 1.643 min.

[0116] N-(3-(benzyl(methyl)amino)propyl)-5-(4-fluorophenyl)thiophene-2-car- boxamide (14). Prepared from / V-(3-(benzyl(methyl)amino)propyl)-5-bromothiophene-2- carboxamide (2, 0.26 mmol) and 2-(4-fluorophenyl)-4,4,5,5-tetramethyl-1 ,3,2-dioxaboro- lane (0.29 mmol, 1.1 eq.) according to general procedure 2. Purification by flash chroma- tography with DCM / MeOH (2-6%). Yield: 20 mg (18%), brown semi-solid.1H NMR (400 MHz, CDCI3) δ 8.16 (s, 1 H), 7.59 - 7.49 (m, J = 8.1 , 5.1 , 2.5 Hz, 2H), 7.33 - 7.27 (m, J = 8.1 , 3.9 Hz, 5H), 7.25 - 7.22 (m, J = 3.7 Hz, 1 H), 7.14 - 7.02 (m, 3H), 3.59 - 3.51 (m, 4H), 2.67 - 2.58 (m, 2H), 2.29 (s, 3H), 1.86 - 1.76 (m, 2H).13C NMR (101 MHz, CDCI3) δ 164.14, 161.75, 147.19, 138.49, 138.08, 130.15, 130.12, 129.69, 128.83, 128.59, 127.96, 127.88, 127.59, 123.38, 116.23, 116.02, 63.33, 57.27, 41.65, 40.54, 25.29. TLC-MS (ESI+): calcd. m / z 382.15 for C22H23FN2OS. Found 383.2 [M+H]+. HPLC fa = 5.957 min.

[0117] N-(3-(benzyl(methyl)amino)propyl)-5-(2-fluorophenyl)thiophene-2-car- boxamide (15). Prepared from A / -(3-(benzyl(methyl)amino)propyl)-5-bromothiophene-2- carboxamide (2, 0.22 mmol) and (2-fluorophenyl)boronic acid (0.24 mmol, 1.1 eq.) accord- ing to general procedure 2. Purification by flash chromatography with DCM / MeOH (2- 6%). Yield: 20 mg (22%), brown semi-solid.1H NMR (400 MHz, CDCI3) δ 8.14 (s, 1 H), 7.54 (t, 1 H), 7.33 - 7.29 (m, J = 3.0 Hz, 1 H), 7.29 - 7.20 (m, 7H), 7.17 - 7.06 (m, J = 16.5, 8.6 Hz, 2H), 3.59 - 3.44 (m, 4H), 2.58 (t, 2H), 2.26 (s, 3H), 1 .77 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 161.79, 160.58, 158.09, 141.14, 141.11 , 139.17, 139.14, 137.96, 129.70, 129.66, 129.61 , 128.98, 128.95, 128.59, 128.47, 127.60, 126.78, 126.71 , 124.71, 124.67, 121.82, 121.69, 116.68, 116.46, 63.24, 56.98, 41.69, 40.45, 25.28. TLC-MS (ESI+): calcd. m / z 382.15 for C22H23FN2OS. Found 383.2 [M+H]+. HPLC fa = 6.044 min.

[0118] N-(3-(benzyl(methyl)amino)propyl)-5-(3-fluorophenyl)thiophene-2-car- boxamide (16). Prepared from / V-(3-(benzyl(methyl)amino)propyl)-5-bromothiophene-2- carboxamide (2, 0.22 mmol) and (3-fluorophenyl)boronic acid (0.24 mmol, 1.1 eq.) accord- ing to general procedure 2. Purification by flash chromatography with DCM / MeOH (4- 8%). Yield: 63 mg (72%), brown semi-solid.1H NMR (400 MHz, CDCI3) δ 8.13 (s, 1 H), 7.35 - 7.22 (m, 8H), 7.21 (d, J = 3.9 Hz, 1 H), 7.13 (d, J = 3.9 Hz, 1 H), 7.02 - 6.93 (m, 1 H),3.56 - 3.46 (m, 4H), 2.58 (t, 2H), 2.24 (s, 3H), 1 .76 (quint, 2H).13C NMR (101 MHz, CDCh) 8 163.14, 161.57, 146.66, 139.17, 138.34, 135.95, 130.97, 130.71 , 129.60, 129.60, 128.77, 128.55, 128.55, 127.54, 124.06, 121.85, 115.07, 113.09, 63.40, 57.39, 41 .73, 40.63, 25.36. TLC-MS (ESI+): calcd. m / z 382.15 for C22H23FN2OS. Found 383.2 [M+H]+. HPLC tR= 5.940 min.

[0119] N-(3-(benzyl(methyl)amino)propyl)-5-(3, 5-difluorophenyl)thiophene-2- carboxamide (17). Prepared from / V-(3-(benzyl(methyl)amino)propyl)-5-bromothiophene-2- carboxamide (2, 0.19 mmol) and (3,5-difluorophenyl)boronic acid (0.21 mmol, 1.1 eq.) ac- cording to general procedure 2. Purification by flash chromatography with DCM / MeOH (2- 7%). Yield: 26 mg (31%), brown semi-solid.1H NMR (400 MHz, CDCI3) δ 8.31 (s, 1 H), 7.33 - 7.26 (m, 5H), 7.18 (dd, J = 18.3, 3.9 Hz, 2H), 7.10 - 7.01 (m, 2H), 6.82 - 6.72 (m, 1 H), 3.59 - 3.50 (m, 4H), 2.66 - 2.61 (m, 2H), 2.28 (s, 3H), 1 .80 (quint, J = 11 .5, 5.8 Hz, 2H).13C NMR (101 MHz, CDCI3) δ 163.36, 161.39, 145.39, 139.79, 138.28, 136.81 , 129.71 , 128.82, 128.60, 127.65, 124.74, 109.05, 103.57, 63.49, 57.71 , 41.66, 40.92, 25.12. TLC-MS (ESI+): calcd. m / z 400.14 for C22H22F2N2OS. Found 401 .2 [M+H]+. HPLC tR= 6.630 min.

[0120] N-(3-((4-methoxybenzyl)(methyl)amino)propyl)-5-phenylthiophene-2-car- boxamide (18). Prepared from 5-phenylthiophene-2-carboxylic acid (0.29 mmol) and A / 1- (4-methoxybenzyl)-A / 1-methylpropane-1 ,3-diamine dihydrochloride (18a, 0.29 mmol, 1 eq.) according to general procedure 1 . Purification by flash chromatography with DCM / MeOH (1-4%). Yield: 33 mg (28%), brown semi-solid.1H NMR (400 MHz, CDCI3) δ 8.20 (s, 1 H), 7.61 - 7.55 (m, J = 7.1 , 4.8, 2.6 Hz, 2H), 7.42 - 7.36 (m, 2H), 7.35 - 7.28 (m, J = 11 .8, 6.0, 2.6 Hz, 2H), 7.25 - 7.21 (m, J = 8.6 Hz, 2H), 7.19 (d, J = 3.9 Hz, 1 H), 6.87 - 6.79 (m, 2H), 3.74 (s, 3H), 3.59 - 3.49 (m, 4H), 2.64 (t, 2H), 2.31 (s, 3H), 1 .83 (quint, J = 11 .4, 5.8 Hz, 2H).13C NMR (101 MHz, CDCI3) δ 161.93, 159.23, 148.35, 133.83, 131.25, 131.00, 129.23, 129.15, 129.05, 128.47, 126.16, 123.45, 113.97, 62.51, 55.34, 29.85, 25.11 , 22.84, 14.27. TLC-MS (ESI+): calcd. m / z 394.17 for C23H26N2O2S. Found 395.2 [M+H]+. HPLC fR= 6.072 min.

[0121] N-(3-((4-bromobenzyl)(methyl)amino)propyl)-5-phenylthiophene-2-car- boxamide (19). Prepared from 5-phenylthiophene-2-carboxylic acid (0.29 mmol) and A / 1-(4-brornobenzyl)- / V1-methylpropane-1 ,3-diamine dihydrochloride (19a, 0.29 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (1-4%). Yield: 63 mg (48%), yellow semi-solid.1H NMR (400 MHz, CDCI3) δ 7.92 (t, J =4.6 Hz, 1 H), 7.59 - 7.51 (m, J = 5.2, 3.3 Hz, 2H), 7.43 - 7.33 (m, 4H), 7.32 - 7.25 (m, 2H), 7.20 - 7.13 (m, J = 5.9, 5.1 Hz, 3H), 3.57 - 3.42 (m, J = 11.7, 5.7 Hz, 4H), 2.58 (t, J = 5.9 Hz, 2H), 2.25 (s, 3H), 1.78 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 161.99, 148.51 , 137.87, 136.94, 133.60, 131.65, 131.23, 129.15, 129.08, 128.49, 126.09, 123.48, 121.48, 62.39, 56.84, 41.48, 40.05, 25.42. TLC-MS (ESI+): calcd. m / z 442.07 for C22H23BrN2OS. Found 465.1 [M+Na]+. HPLC fR= 6.856 min.

[0122] N-(3-((4-fluorobenzyl)(methyl)amino)propyl)-5-phenylthiophene-2-car- boxamide (20). Prepared from 5-phenylthiophene-2-carboxylic acid (0.44 mmol) and A / 1- (4-fluorobenzyl)-A / 1-methylpropane-1 ,3-diamine dihydrochloride (20a, 0.44 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (1-6%). Yield: 90 mg (53%), brown semi-solid.1H NMR (400 MHz, CDCI3) δ 8.05 (s, 1H), 7.54 (d, J = 9.6 Hz, 2H), 7.40 - 7.33 (m, 2H), 7.33 - 7.29 (m, 2H), 7.28 - 7.23 (m, J = 8.1 , 5.3 Hz, 2H), 7.17 (d, J = 3.8 Hz, 1 H), 6.96 (t, J = 8.6 Hz, 2H), 3.54 - 3.48 (m, 4H), 2.62 (t, J = 18.0, 12.1 Hz, 2H), 2.26 (s, 3H), 1.79 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 162.22, 162.05, 148.54, 137.89, 133.59, 133.45, 131.19, 129.10, 129.07, 128.50, 126.07,123.42, 115.38, 62.21, 56.77, 41.32, 40.10, 25.35. TLC-MS (ESI+): calcd. m / z 382.15 for C2OH23FN2OS. Found 383.2 [M+H]+. HPLC fR= 6.094 min.

[0123] N-(3-((2-fluorobenzyl)(methyl)amino)propyl)-5-phenylthiophene-2-car- boxamide (21). Prepared from 5-phenylthiophene-2-carboxylic acid (0.29 mmol) and A / 1- (2-fluorobenzyl)-A / 1-methylpropane-1,3-diamine dihydrochloride (21a, 0.29 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (1^t%). Yield: 100 mg (89%), yellow semi-solid.1H NMR (400 MHz, CDCI3) δ 8.16 (t, J =4.7 Hz, 1H), 7.57 - 7.51 (m, 2H), 7.37 - 7.22 (m, 6H), 7.15 (d, J = 3.9 Hz, 1H), 7.10 - 7.04 (m, 1 H), 7.04 - 6.97 (m, J = 9.5, 8.2, 1.0 Hz, 1 H), 3.66 (s, 2H), 3.52 (q, 2H), 2.68 (t, J = 13.8, 7.9 Hz, 2H), 2.31 (s, 3H), 1.81 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 162.88, 162.11, 160.42, 148.41, 138.14, 133.73, 132.24, 132.20, 129.82, 129.73, 129.07, 128.93,128.42, 126.09, 124.24, 124.20, 123.43, 115.80, 115.58, 57.02, 55.69, 53.55, 41.24,40.17, 25.23. TLC-MS (ESI+): calcd. m / z 382.15 for C22H23FN2OS. Found 383.2 [M+H]+. HPLC fR= 5.901 min.

[0124] N-(3-((3-fluorobenzyl)(methyl)amino)propyl)-5-phenylthiophene-2-car- boxamide (22). Prepared from 5-phenylthiophene-2-carboxylic acid (0.29 mmol) and N'- (3-fluorobenzyl)-A / 1-methylpropane-1 ,3-diamine dihydrochloride (22a, 0.29 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (1-4%). Yield: 33 mg (29%), yellow semi-solid.1H NMR (400 MHz, CDCI3) δ 7.88 (t, J = 4.4 Hz, 1 H), 7.59 - 7.52 (m, 2H), 7.41 - 7.34 (m, 2H), 7.33 - 7.28 (m, 2H), 7.25 - 7.16 (m, 2H), 7.11 - 7.00 (m, 2H), 6.98 - 6.90 (m, 1 H), 3.60 - 3.49 (m, 4H), 2.60 (t, 2H), 2.27 (s, 3H), 1.80 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 164.19, 161.97, 161.74, 148.49, 140.71 , 138.04, 133.72, 130.13, 130.05, 129.11 , 128.96, 128.49, 126.15, 125.11, 125.08, 123.48, 116.40, 116.19, 114.59, 114.38, 62.69, 57.05, 41.64, 40.17, 25.52. TLC-MS (ESI+): calcd. m / z 382.15 for C22H23FN2OS. Found 383.2 [M+H]+. HPLC tR= 6.155 min.

[0125] N-(3-(benzyl(ethyl)amino)propyl)-5-phenylthiophene-2-carboxamide(23). Prepared from 5-phenylthiophene-2-carboxylic acid (0.44 mmol) and Af-benzyl-A / 1- ethylpropane-1,3-diamine dihydrochloride (23a, 0.44 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (1-6%). Yield: 70 mg (42%), brown semi-solid.1H NMR (400 MHz, CDCI3) δ 7.94 (s, 1 H), 7.61 - 7.52 (m, 2H), 7.39 - 7.33 (m, J = 10.1, 4.7 Hz, 2H), 7.32 - 7.26 (m, J = 8.3, 5.6, 3.3 Hz, 4H), 7.26 - 7.21 (m, 3H), 7.16 (d, J = 3.9 Hz, 1H), 3.58 (s, 2H), 3.47 (q, J = 7.8, 3.9 Hz, 2H), 2.66 - 2.52 (m, 4H), 1.75 (quint, 2H), 1.08 (t, J = 7.1 Hz, 3H).13C NMR (101 MHz, CDCI3) δ 161.90,148.32, 138.52, 138.28, 133.76, 129.53, 129.08, 128.80, 128.51, 128.41, 127.38, 126.09,123.33, 58.43, 52.45, 47.05, 40.34, 25.23, 11.11. TLC-MS (ESI+): calcd. m / z 378.18 for C23H26N2OS. Found 379.2 [M+H]+. HPLC fR= 6.043 min.

[0126] N-(3-(benzyl(isopropyl)amino)propyl)-5-phenylthiophene-2-carboxamide(24). Prepared from 5-phenylthiophene-2-carboxylic acid (0.42 mmol) and Af-benzyl-A / 1- isopropylpropane-1,3-diamine dihydrochloride (24a, 0.42 mmol, 1 eq.) according to gen- eral procedure 1. Purification by flash chromatography with DCM / MeOH (0-3%). Yield: 30 mg (18%), yellow semi-solid.1H NMR (400 MHz, CDCI3) δ 7.65 - 7.56 (m, 2H), 7.45 - 7.32 (m, 6H), 7.31 - 7.22 (m, J = 10.2, 6.9, 2.7 Hz, 3H), 7.19 - 7.12 (m, J = 15.7, 3.8 Hz,2H), 3.56 (s, 2H), 3.51 - 3.44 (m, J = 11.6, 5.4 Hz, 2H), 3.15 - 3.01 (m, 1 H), 2.60 (t, 2H), 1.72 (quint, J = 11.6, 5.9 Hz, 2H), 1.07 (d, J = 6.6 Hz, 6H).13C NMR (101 MHz, CDCI3) δ 161.85, 148.36, 140.19, 138.31 , 133.83, 129.39, 129.12, 128.74, 128.54, 128.44, 127.22,126.15, 123.28, 54.26, 49.00, 47.99, 39.94, 26.08, 17.52. TLC-MS (ESI+): calcd. m / z 392.19 for C24H28N2OS. Found 393.2 [M+H]+. HPLC tR= 5.511 min.

[0127] N-(3-(benzyl(cyclopropyl)amino)propyl)-5-phenylthiophene-2-carboxa- mide (25). Prepared from 5-phenylthiophene-2-carboxylic acid (0.54 mmol) and / V1-benzyl- A / 1-cyclopropylpropane-1 ,3-diamine (25a, 0.54 mmol, 1 eq.) according to general proce- dure 1. Purification by flash chromatography with PE / EtOAc (10-40%). Yield: 55 mg (26%), yellow semi-solid.1H NMR (400 MHz, CDCI3) δ 7.65 - 7.55 (m, J = 5.2, 3.4 Hz, 2H), 7.42 - 7.35 (m, 2H), 7.34 - 7.29 (m, 1 H), 7.28 - 7.19 (m, 8H), 3.76 (s, 2H), 3.44 (q, J = 11.6, 5.7 Hz, 2H), 2.71 (t, 2H), 1.86 - 1 .72 (m, 3H), 0.57 - 0.51 (m, 2H), 0.50 - 0.44 (m, 2H).13C NMR (101 MHz, CDCI3) δ 161.76, 148.35, 138.11 , 137.85, 133.79, 129.88,129.16, 128.85, 128.50, 128.33, 127.34, 126.17, 123.40, 60.04, 54.37, 40.31, 37.65, 25.37, 7.37. TLC-MS (ESI+): calcd. m / z 390.18 for C24H26N2OS. Found 391.2 [M+H]+. HPLC fR= 6.192 min.

[0128] N-(3-(benzyl(propyl)amino)propyl)-5-phenylthiophene-2-carboxamide(26). Prepared from 5-phenylthiophene-2-carboxylic acid (0.36 mmol) and / V-benzyl-A / 1- propylpropane-1,3-diamine dihydrochloride (26a, 0.36 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (1-4%). Yield: 36 mg (26%), colorless oil.1H NMR (400 MHz, CDCI3) δ 7.66 - 7.56 (m, 3H), 7.46 - 7.30 (m, 8H), 7.22 (d, J = 3.9 Hz, 1H), 3.88 (s, 2H), 3.51 (q, 2H), 2.87 (s, 2H), 2.80 (s, 1 H), 2.70 (t, 2H), 1.95 (quint, 2H), 1.71 - 1.56 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H).13C NMR (101 MHz, CDCI3) δ 163.47, 149.50, 136.79, 133.57, 129.99, 129.73, 129.18, 129.07, 128.68, 126.18, 123.86, 58.37, 54.95, 51.91, 38.72, 25.20, 18.62, 11.56. TLC-MS (ESI+): calcd. m / z 392.19 for C24H28N2OS. Found 393.2 [M+H]+. HPLC tR= 6.351 min.

[0129] N-(3-(benzyl(butyl)amino)propyl)-5-phenylthiophene-2-carboxamide(27). Prepared from 5-phenylthiophene-2-carboxylic acid (0.46 mmol) and Af-benzyl-A / 1- butylpropane-1,3-diamine dihydrochloride (27a, 0.46 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (0-3%). Yield: 13 mg(7%), yellow solid.1H NMR (400 MHz, CDCI3) δ 7.66 - 7.53 (m, J = 5.3, 3.3 Hz, 3H), 7.43- 7.37 (m, 2H), 7.36 - 7.22 (m, 7H), 7.20 (d, J = 3.8 Hz, 1 H), 3.60 (s, 2H), 3.50 (q, J =11 .5, 5.5 Hz, 2H), 2.60 (t, 2H), 2.51 (t, 2H), 1 .77 (quint, J = 11.4, 5.8 Hz, 2H), 1.60 - 1.48 (m, 2H), 1.35 - 1.26 (m, J = 15.0, 7.4 Hz, 2H), 0.88 (t, J = 7.3 Hz, 3H).13C NMR (101 MHz, CDCI3) δ 161.91 , 148.39, 138.33, 133.86, 129.57, 129.15, 128.81 , 128.57, 128.47, 127.43, 126.18, 123.35, 59.08, 53.64, 52.94, 40.09, 28.73, 25.55, 20.87, 14.18. TLC-MS (ESI+): calcd. m / z 406.21 for C25H30N2OS. Found 407.2 [M+H]+. HPLC fa = 6.820 min.

[0130] N-(3-(benzyl(3-hydroxypropyl)amino)propyl)-5-phenylthiophene-2-car- boxamide (28). Prepared from 5-phenylthiophene-2-carboxylic acid (1.2 mmol) and 3-((3- aminopropyl)(benzyl)amino)propan-1-ol dihydrochloride (28a, 1.2 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (0-4%). Yield: 25 mg (5%), colorless oil.1H NMR (400 MHz, CDCI3) δ 7.62 - 7.55 (m, 2H), 7.43 (d, J = 3.9 Hz, 1 H), 7.41 - 7.25 (m, 8H), 7.22 (d, J = 3.9 Hz, 1 H), 7.10 (t, J = 6.0 Hz, 1 H), 4.24 (s, 1 H), 3.79 - 3.71 (m, 4H), 3.44 (q, J = 6.3 Hz, 2H), 2.82 (t, J = 6.1 Hz, 2H), 2.71 (t, J = 6.6 Hz, 2H), 1.91 (quint, J = 6.5 Hz, 2H), 1.80 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 162.68, 149.13, 137.49, 135.78, 133.66, 129.74, 129.29, 129.18, 128.95, 128.62, 128.29, 126.18, 123.72, 63.18, 58.69, 53.57, 50.97, 37.63, 27.34, 25.88. TLC-MS (ESI+): calcd. m / z 408.19 for C24H28N2O2S. Found 431.3 [M+Na]+. HPLC fa = 5.528 min.

[0131] N-(3-(benzyl(phenethyl)amino)propyl)-5-phenylthiophene-2-carboxamide (29). Prepared from 5-phenylthiophene-2-carboxylic acid (0.45 mmol) and A / 1-benzyl- / V1- phenethylpropane-1 ,3-diamine dihydrochloride (29a, 0.45 mmol, 1 eq.) according to gen- eral procedure 1. Purification by flash chromatography with PE / EtOAc (0-60%). Yield: 24 mg (12%), white solid.1H NMR (400 MHz, CDCI3) δ 7.63 - 7.50 (m, 2H), 7.38 - 7.31 (m, 2H), 7.30 - 7.16 (m, 9H), 7.16 - 7.04 (m, 5H), 3.63 (s, 2H), 3.39 (q, J = 5.7 Hz, 2H), 2.86- 2.70 (m, 4H), 2.61 (t, J = 5.9 Hz, 2H), 1.71 (quint, J = 6.0 Hz, 2H).13C NMR (101 MHz, CDCI3) δ 161.86, 148.42, 140.30, 138.92, 138.20, 133.81, 129.44, 129.13, 128.82, 128.79, 128.56, 128.47, 127.42, 126.23, 126.17, 123.35, 59.01, 55.52, 52.59, 39.80, 33.04, 25.87. TLC-MS (ESI+): calcd. m / z 454.21 for C29H3oN2OS. Found 477.1 [M+Na]+. HPLC fa = 7.138 min.

[0132] N-(3-(benzyl(3-phenylpropyl)amino)propyl)-5-phenylthiophene-2-car- boxamide (30). Prepared from 5-phenylthiophene-2-carboxylic acid (0.42 mmol) and N'- benzyl-A / 1-(3-phenylpropyl)propane-1,3-diamine dihydrochloride (30a, 0.42 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (0-6%). Yield: 19 mg (10%), colorless oil.1H NMR (400 MHz, CDCI3) δ 7.62 (d, 2H), 7.45 - 7.13 (m, 15H), 3.64 (s, 2H), 3.58 - 3.40 (m, 3H), 2.79 - 2.48 (m, 6H), 1.91 (quint, J = 9.9, 7.5 Hz, 2H), 1.79 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 162.02, 148.49, 141.92, 138.58, 138.01 , 133.77, 129.51 , 129.14, 129.00, 128.59, 128.50, 128.41 , 127.46, 126.17, 125.98, 123.41 , 59.00, 53.30, 52.80, 39.84, 33.78, 28.33, 25.70. TLC-MS (ESI+): calcd. m / z 468.22 for C30H32N2OS. Found 491.2 [M+Na]+. HPLC fa = 7.457 min.

[0133] N-(3-(benzyl(ethyl)amino)propyl)-5-(3-fluorophenyl)thiophene-2-carboxa- mide (31). Prepared from N-(3-(benzyl(ethyl)amino)propyl)-5-bromothiophene-2-carbox- amide (31a, 0.29 mmol) and (3-fluorophenyl)boronic acid (0.32 mmol, 1.1 eq.) according to general procedure 2. Purification by flash chromatography with DCM / MeOH (1-4%). Yield: 29 mg (25%), brown semi-solid.1H NMR (400 MHz, CDCI3) δ 7.98 (s, 1 H), 7.39 - 7.25 (m, 8H), 7.24 - 7.21 (m, 1 H), 7.18 (d, J = 3.9 Hz, 1 H), 7.06 - 6.98 (m, 1H), 3.60 (s, 2H), 3.51 (q, J = 11.2, 4.1 Hz, 2H), 2.69 - 2.57 (m, 4H), 1.78 (quint, J = 11.6, 5.8 Hz, 2H), 1.11 (t, J = 7A Hz, 3H).13C NMR (101 MHz, CDCI3) δ 164.45, 162.00, 161.65, 146.73, 146.70, 139.15, 135.97, 135.89, 130.75, 130.67, 129.62, 128.72, 128.59, 127.48, 124.05, 121.90, 121.87, 115.32, 115.11 , 113.11 , 112.89, 58.59, 52.72, 47.12, 40.58, 25.20, 11.15. TLC-MS (ESI+): calcd. m / z 396.17 for C23H25FN2OS. Found 397.2 [M+H]+. HPLC fa = 6.288 min.

[0134] N-(3-(ethyl(4-fluorobenzyl)amino)propyl)-5-(3-fluorophenyl)thiophene-2- carboxamide (32). Prepared from 5-bromo-N-(3-(ethyl(4-fluorobenzyl)amino)propyl)thio- phene-2-carboxamide (32a, 0.33 mmol) and (3-fluorophenyl)boronic acid (0.36 mmol, 1.1 eq.) according to general procedure 2. Purification by flash chromatography with DCM / MeOH (1^1%). Yield: 53 mg (40%), brown semi-solid.1H NMR (400 MHz, CDCI3) δ 7.83 (s, 1 H), 7.40 - 7.33 (m, 2H), 7.30 - 7.23 (m, 4H), 7.20 (d, J = 3.9 Hz, 1 H), 7.06 - 6.99 (m, J = 8.1 , 5.7, 3.5 Hz, 1 H), 6.99 - 6.92 (m, 2H), 3.56 (s, 2H), 3.51 (q, J = 11.5, 5.4 Hz, 2H), 2.67 - 2.50 (m, 4H), 1.78 (quint, J = 11.7, 5.9 Hz, 2H), 1.10 (t, J = 7.1 Hz, 3H).13C NMR (101 MHz, CDCI3) δ 164.45, 163.42, 162.00, 161.63, 160.98, 146.82, 146.79,138.96, 135.88, 135.80, 131.11 , 131.03, 130.79, 130.71 , 129.87, 128.75, 124.07, 121.91 , 121.89, 115.50, 115.40, 115.29, 115.19, 113.11 , 112.89, 57.74, 52.46, 47.02, 40.44, 25.29, 11.16. TLC-MS (ESI+): calcd. m / z 414.16 for C23H24F2N2OS. Found 415.2 [M+H]+. HPLC fR= 6.443 min.

[0135] tert-butyl (3-(5-phenylthiophene-2-carboxamido)propyl)carbamate (33). Prepared from 5-phenylthiophene-2-carboxylic acid (2.01 mmol) and terf-butyl (3-ami- nopropyl)carbamate (2.01 mmol, 1 eq.) according to general procedure 1. Purification by suction filtration and wash with water. Yield: 637 mg (88%), brown solid.1H NMR (400 MHz, DMSO) δ 8.49 (t, 1 H), 7.76 - 7.65 (m, J = 7.9, 5.9 Hz, 3H), 7.53 (d, J = 3.9 Hz, 1 H), 7.44 (t, J = 7.6 Hz, 2H), 7.39 - 7.33 (m, J = 7.3 Hz, 1 H), 6.80 (t, J = 5.0 Hz, 1 H), 3.24 (q, J = 13.0, 6.7 Hz, 2H), 2.98 (q, J = 12.9, 6.6 Hz, 2H), 1.63 (quint, J = 6.9 Hz, 2H), 1.38 (s, 9H).13C NMR (101 MHz, DMSO) δ 160.87, 155.58, 147.15, 139.02, 133.13, 129.20, 128.84, 128.41 , 125.59, 124.19, 77.48, 39.52, 37.72, 36.88, 29.64, 28.23. TLC-MS (ESI+): calcd. m / z 360.15 for CI9H24N2O3S. Found 382.8 [M+Na]+. HPLC fR= 8.697 min.

[0136] N-(3-(benzylamino)propyl)-5-phenylthiophene-2-carboxamide (34). Pre- pared from benzaldehyde (0.51 mmol), A / -(3-aminopropyl)-5-phenylthiophene-2-carbox- amide hydrochloride (34a, 0.51 mmol, 1 eq.), and triethylamine according to general pro- cedure 3. Purification by flash chromatography with DCM / MeOH (1-10%). Yield: 53 mg (30%), pale yellow solid.1H NMR (400 MHz, DMSO) δ 8.78 (t, J = 5.8 Hz, 1H), 8.21 (s, 1 H), 7.79 (d, J = 3.9 Hz, 1 H), 7.75 - 7.65 (m, 2H), 7.56 - 7.30 (m, 8H), 4.02 (s, 2H), 3.32 (q, J = 6.5 Hz, 2H), 2.85 (t, J = 7.4 Hz, 2H), 1.87 (quint, J = 6.8 Hz, 2H).13C NMR (101 MHz, DMSO) δ 161.08, 147.28, 138.82, 134.55, 133.10, 129.41, 129.22, 129.15, 128.47, 128.44, 128.17, 125.61, 124.23, 50.80, 44.99, 36.61, 26.83. TLC-MS (ESI+): calcd. m / z 350.15 for C21H22N2OS. Found 372.9 [M+Na]+. HPLC fR= 5.935 min.

[0137] N-(3-(3,4-dihydroisoquinolin-2( 1H)-yl)propyl)-5-phenylthiophene-2-car- boxamide (35). Prepared from 5-phenylthiophene-2-carboxylic acid (0.53 mmol) and 3- (3,4-dihydroisoquinolin-2(1H)-yl)propan-1 -amine dihydrochloride (35a, 0.53 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH / 1% NH3(1.5-2%). Yield: 17 mg (9%), yellow semi-solid.1H NMR (400 MHz, CDCI3) δ 8.74 (s, 1 H), 7.40 - 7.27 (m, 5H), 7.25 - 7.12 (m, 3H), 7.09 - 7.04 (m, J = 7.3Hz, 1 H), 7.02 (d, J = 3.9 Hz, 1 H), 6.91 (d, J = 3.9 Hz, 1 H), 3.75 (s, 2H), 3.62 (dd, J = 11.0, 5.1 Hz, 2H), 3.00 (t, J = 5.9 Hz, 2H), 2.85 (t, J = 6.0 Hz, 2H), 2.79 (t, 2H), 1 .89 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 161.83, 147.98, 138.07, 134.31 , 134.18, 133.70, 129.15, 128.98, 128.82, 128.27, 126.92, 126.69, 126.11 , 126.07, 123.25, 58.85, 56.23, 51.52, 41 .42, 29.38, 24.24. TLC-MS (ESI+): calcd. m / z 376.16 for C23H24N2OS. Found 399.3 [M+Na]+. HPLC fa = 5.191 min.

[0138] N-(3-((3-(4-fluorobenzamido)benzyl)(methyl)amino)propyl)-5- phenylthiophene-2-carboxamide (36). Prepared from 5-phenylthiophene-2-carboxylic acid (0.34 mmol) and A / -(3-(((3-aminopropyl)(methyl)amino)methyl)phenyl)-4-fluorobenzamide (36a, 0.34 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatog- raphy with DCM / MeOH (5-8%). Yield: 96 mg (56%), pale yellow solid.1H NMR (400 MHz, DMSO) δ 10.35 (s, 1 H), 8.63 (s, 1 H), 8.09 - 8.00 (m, 2H), 7.92 (s, 1 H), 7.75 - 7.62 (m, 4H), 7.52 (d, J = 3.9 Hz, 1 H), 7.44 (dd, J = 10.3, 4.7 Hz, 2H), 7.37 (dd, J = 12.3, 5.2 Hz, 4H), 7.18 (s, 1 H), 4.02 (s, 1 H), 3.55 - 3.22 (m, 3H), 2.33 (s, 2H), 1.98 - 1.72 (m, 2H), 1.29 - 0.63 (m, 3H).13C NMR (101 MHz, DMSO) δ 165.35, 164.48, 162.87, 161.10, 147.30, 139.26, 138.83, 133.11 , 131.24, 130.45, 130.36, 129.24, 129.06, 128.80, 128.49, 125.62, 124.22, 115.46, 115.24, 54.91 , 45.66, 36.96, 21.06, 8.60. TLC-MS (ESI+): calcd. m / z 501.19 for C29H28FN3O2S. Found 502.2 [M+H]+. HPLC fa = 6.709 min.

[0139] N-(tert-butyl)-1-(3-(5-phenylthiophene-2-carboxamido)propyl)piperidine- 4-carboxamide (37). Prepared from 5-phenylthiophene-2-carboxylic acid (0.48 mmol) and 1-(3-aminopropyl)-A / -(tert-butyl)piperidine-4-carboxamide dihydrochloride (37a, 0.48 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (10-20%). Yield: 940 mg (46%), white solid.1H NMR (400 MHz, CDCI3) δ 8.14 (t, 1 H), 7.70 - 7.66 (m, 2H), 7.56 (d, J = 3.9 Hz, 1 H), 7.43 - 7.37 (m, 2H), 7.33 - 7.30 (m, J = 3.3, 1.2 Hz, 1 H), 7.30 (d, J = 3.9 Hz, 1 H), 5.25 (s, 1 H), 3.55 (q, J = 11.2, 5.4 Hz, 2H), 3.08 (d, J = 11.1 Hz, 2H), 2.53 (t, 2H), 2.04 - 1.82 (m, 7H), 1.77 (dt, J = 11.5, 5.9 Hz, 2H), 1.33 (s, 9H).13C NMR (101 MHz, CDCI3) δ 174.1, 162.0, 148.4, 137.9, 133.8, 129.5, 129.2, 128.4, 126.3, 123.6, 58.9, 53.7, 51.1, 41.0, 29.2, 29.0, 24.5. TLC-MS (ESI+): calcd. m / z 427.23 for C24H33N3O2S. Found 428.4 [M+H]+. HPLC fa = 5.982 min.

[0140] tert-butyl 3-((5-phenylthiophene-2-carboxamido)methyl)piperidine-1-car- boxylate (38). Prepared from 5-phenylthiophene-2-carboxylic acid (1.47 mmol) and fert- butyl 3-(aminomethyl)piperidine-1 -carboxylate (1.47 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (0-1 %). Yield: 588 mg (quant.), yellow oil.1H NMR (400 MHz, CDCI3) δ 7.63 - 7.55 (m, 2H), 7.52 (d, J = 3.9 Hz, 1 H), 7.41 - 7.33 (m, J = 7.4 Hz, 2H), 7.33 - 7.27 (m, J = 7.3 Hz, 1 H), 7.22 (d, J = 3.9 Hz, 1 H), 3.93 - 3.40 (m, J = 46.9 Hz, 3H), 3.35 - 2.98 (m, J = 39.8, 28.9 Hz, 2H), 2.97 - 2.74 (m, J = 47.8, 19.7 Hz, 2H), 1.95 - 1.76 (m, 2H), 1.70 - 1.56 (m, 1 H), 1.44 (s, 9H), 1.41 - 1.18 (m, J = 21.7, 16.4, 7.7 Hz, 2H).13C NMR (101 MHz, CDCI3) δ 162.15, 155.28, 148.79, 137.94, 133.67, 129.07, 129.07, 128.87, 128.45, 128.45, 126.12, 123.51 , 79.71 , 47.06, 45.14, 41.58, 35.62, 28.51 , 28.51 , 28.51 , 28.19, 23.66. TLC-MS (ESI+): calcd. m / z 400.18 for C22H28N2O3S. Found 423.2 [M+Na]+. HPLC fR= 9.442 min.

[0141] N-((1-benzylpiperidin-3-yl)methyl)-5-phenylthiophene-2-carboxamide (39). Prepared from 5-phenylthiophene-2-carboxylic acid (0.5 mmol) and (1-benzylpiperi- din-3-yl)methanamine hydrochloride (39a, 0.5 mmol, 1 eq.) according to general proce- dure 1. Purification by flash chromatography with DCM / MeOH (1-6%). Yield: 26 mg (14%), yellow oil.1H NMR (400 MHz, CDCI3) δ 7.60 - 7.48 (m, 2H), 7.43 - 6.97 (m, 10H), 6.63 (s, 1 H), 3.46 (dd, 2H), 3.37 - 3.19 (m, 2H), 2.82 - 2.42 (m, 2H), 2.27 - 2.00 (m, 2H), 1.96 - 1.80 (m, 1 H), 1.73 - 1.59 (m, 2H), 1.58 - 1.44 (m, 1 H), 1.16 - 1.03 (m, 1 H).13C NMR (101 MHz, CDCI3) δ 162.09, 148.72, 137.94, 137.39, 133.71, 129.54, 129.15, 128.97, 128.54, 128.43, 127.44, 126.18, 123.49, 63.35, 57.43, 53.90, 43.81 , 35.60, 28.26, 24.11. TLC-MS (ESI+): calcd. m / z 390.18 for C24H26N2OS. Found 390.9 [M+H]+. HPLC fa = 5.838 min.

[0142] (4-benzyl- 1, 4-diazepan-1-yl)(5-phenylthiophen-2-yl)methanone (40). Prepared from 2-phenylthiazole-4-carboxylic acid (0.5 mmol) and 1-benzyl-1 ,4-diazepane (0.5 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (1-3%). Yield: 152 mg (83%), white solid.1H NMR (400 MHz, DMSO) δ 7.70 (d, J = 7.5 Hz, 2H), 7.55 - 7.17 (m, 10H), 3.90 - 3.53 (m, J = 65.5 Hz, 6H), 2.79 - 2.57 (m, 4H), 1.88 (s, 2H).13C NMR (101 MHz, DMSO) δ 162.66, 146.27, 138.99, 137.51 , 132.94, 130.27, 129.25, 128.55, 128.45, 128.21 , 126.91 , 125.68, 123.66, 61.08, 54.42,48.38, 45.81 , 38.25, 28.27. TLC-MS (ESI+): calcd. m / z 376.16 for C23H24N2OS. Found 377.2 [M+H]+. HPLC fR= 5.182 min.

[0143] 4-fluoro-N-(3-((4-(5-phenylthiophene-2-carbonyl)-1,4-diazepan-1- yl)methyl)phenyl)benzamide (41). Prepared from 5-phenylthiophene-2-carboxylic acid (0.27 mmol) and A / -(3-((1 ,4-diazepan-1-yl)methyl)phenyl)-4-fluorobenzamide hydrochlo- ride (41a, 0.27 mmol, 1 eq.) according to general procedure 1. Purification by flash chro- matography with DCM / MeOH (1-3%). Yield: 80 mg (57%), pale yellow solid.1H NMR (400 MHz, CDCI3) δ 8.07 (s, 1 H), 7.85 (s, 2H), 7.70 - 7.53 (m, J = 6.9 Hz, 4H), 7.42 - 7.36 (m, J = 7.4 Hz, 2H), 7.35 - 7.26 (m, 3H), 7.22 (s, 1 H), 7.15 - 7.05 (m, 3H), 3.79 (s, 4H), 3.65 (s, 2H), 2.84 - 2.74 (m, J = 13.7, 8.7 Hz, 2H), 2.70 (s, 2H), 1.96 (quint, 2H).13C NMR (101 MHz, CDCI3) δ 166.24, 164.94, 164.36, 163.73, 138.25, 137.07, 133.59, 131.23, 131.20, 130.19, 129.74, 129.66, 129.18, 129.15, 128.48, 126.19, 125.11 , 122.80, 120.77, 119.46, 115.97, 115.75, 62.27, 54.93, 49.71, 49.05, 46.55, 29.82. TLC-MS (ESI+): calcd. m / z 513.19 for C30H28FN3O2S. Found 536.2 [M+Na]+. HPLC fa = 6.447 min.

[0144] N-(3-nitrobenzyl)-5-phenylthiophene-2-carboxamide (42). Prepared from 5-phenylthiophene-2-carboxylic acid (0.98 mmol) and (3-nitrophenyl)methanamine hydro- chloride (42a, 0.98 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (0-1%). Yield: 230 mg (69%), white solid.1H NMR (400 MHz, CDCI3) δ 8.19 (s, 1 H), 8.11 (d, J = 8.2, 1.3 Hz, 1 H), 7.72 (d, J = 7.8 Hz, 1 H), 7.64 - 7.57 (m, 2H), 7.54 (d, J = 3.9 Hz, 1 H), 7.50 (t, J = 7.9 Hz, 1 H), 7.44 - 7.30 (m, 3H), 7.26 (d, J = 3.8 Hz, 1 H), 6.73 (t, J = 5.6 Hz, 1 H), 4.71 (d, J = 6.1 Hz, 2H).13C NMR (101 MHz, CDCI3) δ 162.24, 149.74, 148.58, 140.63, 136.67, 134.09, 133.45, 129.85, 129.70, 129.24, 128.85, 126.28, 123.69, 122.71 , 122.60, 43.30. TLC-MS (ESI+): calcd. m / z 338.07 for C18H14N2O3S. Found 361 .1 [M+Na]+. HPLC tR= 8.347 min.

[0145] N-(3-(4-fluorobenzamido)benzyl)-5-phenylthiophene-2-carboxamide (43). Prepared from 4-fluorobenzoic acid (0.5 mmol) and A / -(3-aminobenzyl)-5-phenylthio- phene-2-carboxamide (43a, 0.5 mmol, 1 eq.) according to general procedure 1. Purifica- tion by suction filtration and washing with water. Yield: 187 mg (87%), white solid.1H NMR (400 MHz, DMSO) δ 10.29 (s, 1H), 9.12 (s, 1H), 8.36 - 6.84 (m, J = 183.8, 132.7, 90.8 Hz, 15H), 4.38 (d, J = 90.2 Hz, 2H).13C NMR (101 MHz, DMSO) δ 165.28, 164.43, 162.80,160.96, 147.51 , 139.97, 139.19, 138.83, 133.12, 131.34, 130.43, 130.34, 129.23, 128.56, 128.49, 125.66, 124.32, 122.73, 119.16, 119.01 , 115.37, 115.16, 42.55. TLC-MS (ESI+): calcd. m / z 430.12 for C25H19FN2O2S. Found 453.2 [M+Na]+. HPLC fR= 8.786 min.

[0146] N-(2-(1-methylpyrrolidin-2-yl)ethyl)-2-phenylthiazole-4-carboxamide (44). Prepared from 2-phenylthiazole-4-carboxylic acid (0.39 mmol) and 2-(1-methylpyrrolidin-2- yl)ethan-1-amine (0.39 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (10%). Yield: 48 mg (39%), pale brown semi-solid.1H NMR (400 MHz, CDCI3) δ 8.04 (s, 1 H), 7.98 - 7.87 (m, 3H), 7.46 - 7.40 (m, 3H), 3.73 - 3.39 (m, 3H), 3.08 - 2.93 (m, 1 H), 2.80 - 2.71 (m, J = 10.3 Hz, 1 H), 2.69 (s, 3H), 2.39 - 2.02 (m, 4H), 1.99 - 1.84 (m, 2H).13C NMR (101 MHz, CDCI3) δ 168.42, 161.65, 150.51 , 132.79, 130.78, 129.15, 126.73, 123.04, 66.48, 56.16, 39.35, 36.57, 31.07, 29.79, 21.73. TLC-MS (ESI+): calcd. m / z 315.14 for C17H21N3OS. Found 316.2 [M+H]+. HPLC fR= 3.921 min.

[0147] tert-butyl 4-(2-phenylthiazole-4-carbonyl)-1, 4-diazepane-1 -carboxylate (45). Prepared from 2-phenylthiazole-4-carboxylic acid (2.44 mmol) and fert-butyl 1 ,4-di- azepane-1 -carboxylate (2.44 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with PE / EtOAc (10-30%). Yield: 784 mg (83%), yellow oil.1H NMR (400 MHz, DMSO) δ 8.27 - 8.09 (m, J = 26.9, 12.4 Hz, 1 H), 8.04 - 7.91 (m, J = 3.4 Hz, 2H), 7.66 - 7.45 (m, J = 4.1 Hz, 3H), 3.95 - 3.36 (m, 8H), 1.99 - 1 .72 (m, J = 32.8, 15.9 Hz, 2H), 1.47 - 1.20 (m, J = 35.3 Hz, 9H).13C NMR (101 MHz, DMSO) δ 166.4, 163.1 , 154.4, 151.0, 132.6, 130.7, 129.3, 126.3, 126.2, 78.7, 45.3, 34.9, 28.3, 28.0, 27.8, 26.0. TLC-MS (ESI+): calcd. m / z 387.16 for C20H25N3O3S. Found 410.2 [M+Na]+. HPLC tR= 8.982 min.

[0148] tert-butyl 4-(3-(2-phenylthiazole-4-carboxamido)propyl)piperazine-1-car- boxylate (46). Prepared from 2-phenylthiazole-4-carboxylic acid (0.43 mmol) and tert-butyl 4-(3-aminopropyl)piperazine-1-carboxylate (46a, 0.43 mmol, 1 eq.) according to general procedure 1 . Purification by suction filtration and washing with water. Yield: 128 mg (69%), white solid.1H NMR (400 MHz, DMSO) δ 8.65 (t, 1 H), 8.28 (s, 1 H), 8.02 (s, 2H), 7.52 (s, 3H), 3.43 - 3.32 (m, J = 16.8 Hz, 6H), 2.47 - 2.20 (m, 6H), 1 .71 (quint, 2H), 1 .39 (d, J = 17.7 Hz, 9H).13C NMR (101 MHz, DMSO) δ 167.2, 160.2, 153.8, 150.9, 132.5,130.7, 129.2, 126.4, 123.9, 78.7, 56.2, 52.6, 37.9, 28.0, 25.9. TLC-MS (ESI+): calcd. m / z 430.20 for C22H30N4O3S. Found 431 .2 [M+H]+. HPLC fa = 5.651 min.

[0149] tert-butyl 4-(3-(((2-phenylthiazol-4-yl)methyl)amino)propyl)piperazine-1- carboxylate (47). Prepared from 2-phenylthiazole-4-carbaldehyde (0.47 mmol, 1.1 eq.) and tert-butyl 4-(3-aminopropyl)piperazine-1 -carboxylate (46a, 0.43 mmol) according to general procedure 3. Purification by flash chromatography with DCM / MeOH (5-8%). Yield: 13 mg (7%), yellow oil.1H NMR (400 MHz, CDCI3) δ 7.94 - 7.81 (m, J = 6.3, 2.7 Hz, 2H), 7.54 (s, 1 H), 7.48 - 7.40 (m, J = 6.7, 3.5 Hz, 3H), 4.26 (s, 2H), 3.41 (s, 4H), 3.20 (s, 2H), 2.49 (d, J = 33.3 Hz, 6H), 2.00 (quint, 2H), 1.42 (s, 9H).13C NMR (101 MHz, CDCI3) 6169.9, 154.6, 133.0, 130.8, 129.2, 126.7, 119.7, 80.0, 58.1 , 48.8, 46.8, 29.8, 28.5, 22.1 , 14.2. TLC-MS (ESI+): calcd. m / z 416.22 for C22H32N4O2S. Found 417.2 [M+Na]+. HPLC fa = 3.448 min.

[0150] N-benzyl-1-((2-phenylthiazol-4-yl)methyl)piperidine-4-carboxamide (48). Prepared from 2-phenylthiazole-4-carbaldehyde (0.39 mmol, 1 eq.) and A / -benzylpiperi- dine-4-carboxamide hydrochloride (48a, 0.48 mmol) according to general procedure 3. Purification by flash chromatography with DCM / MeOH (2-7%). Yield: 99 mg (71%), white solid.1H NMR (400 MHz, CDCI3) δ 8.00 - 7.89 (m, 2H), 7.45 - 7.37 (m, 3H), 7.35 - 7.22 (m, 5H), 7.13 (s, 1 H), 5.76 (t, 1 H), 4.44 (d, J = 5.6 Hz, 2H), 3.73 (d, J = 0.6 Hz, 2H), 3.07 (dt, J = 8.9, 3.0 Hz, 2H), 2.21 - 2.04 (m, 3H), 1.92 - 1.75 (m, 4H).13C NMR (101 MHz, CDCI3) δ 174.9, 168.0, 155.2, 138.5, 133.9, 130.0, 129.0, 128.9, 127.9, 127.7, 126.7,115.9, 58.7, 53.4, 43.6, 43.5, 29.2. TLC-MS (ESI+): calcd. m / z 391.17 for C23H25N3OS. Found 392.2 [M+H]+. HPLC fa = 5.446 min.

[0151] tert-butyl 4-(2-(benzo[b]thiophene-2-carboxamido)ethyl)piperazine-1-car- boxylate (49). Prepared from benzo[b]thiophene-2-carboxylic acid (0.39 mmol) and tert- butyl 4-(2-aminoethyl)piperazine-1 -carboxylate (0.39 mmol, 1 eq.) according to general procedure 1. Purification by flash chromatography with DCM / MeOH (0-3%). Yield: 7 mg (46%), yellow oil.1H NMR (400 MHz, CDCI3) δ 7.88 - 7.80 (m, J = 10.3, 4.2 Hz, 2H), 7.77 (s, 1 H), 7.49 - 7.33 (m, 2H), 6.95 (t, 1 H), 3.57 (q, J = 11.3, 5.6 Hz, 2H), 3.52 - 3.41 (m, 4H), 2.63 (t, J = 6.0 Hz, 2H), 2.55 - 2.39 (m, 4H), 1.46 (s, 9H).13C NMR (101 MHz, CDCI3) δ 162.4, 154.8, 140.9, 139.2, 138.6, 126.4, 125.3, 125.1, 125.0, 122.8, 80.0, 56.5,52.7, 36.4, 28.5. TLC-MS (ESI+): calcd. m / z 389.18 for C20H27N3O3S. Found 412.2 [M+Na]+. HPLC fa = 5.225 min.Assays

[0152] ACKR3 (i-Arrestin Recruitment Assay. The potency and efficacy of final compounds 1 to 49 were evaluated by ligand-induced recruitment of fi-Arrestin to ACKR3 using a NanoLuc complementation assay (NanoBiT, Promega Corporation, Madison, Wl, USA) in HEK293T cells (Szpakowska, M.; Nevins, A. M.; Meyrath, M.; Rhainds, D.; D'huys, T.; Guite-Vinet, F.; Dupuis, N.; Gauthier, P.-A.; Counson, M.; Kleist, A.; St-Onge, G.; Hanson, J.; Schols, D.; Volkman, B. F.; Heveker, N.; Chevigne, A. Different contribu- tions of chemokine n-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3 / CXCR7 compared with CXCR4 and cxcr3. Br. J. Pharmacol. 2018, 175, 1419-1438; Dixon, A. S.; Schwinn, M. K.; Hall, M. P.; Zimmerman, K.; Otto, P.; Lubben, T. H.; Butler, B. L.; Binkowski, B. F.; Machleidt, T.; Kirkland, T. A.; Wood, M. G.; Eggers, C. T.; Encell, L. P.; Wood, K. V. Nanoluc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chem. Biol. 2016, 11, 400- 408; Meyrath, M.; Palmer, C. B.; Reynders, N.; Vanderplasschen, A.; Ollert, M.; Bouvier, M.; Szpakowska, M.; Chevigne, A. Proadrenomedullin n-terminal 20 peptides (pamps) are agonists of the chemokine scavenger receptor ACKR3 / CXCR7. ACS Pharmacology & Translational Science 2021, 4, 813-823; and Szpakowska, M.; Meyrath, M.; Reynders, N.; Counson, M.; Hanson, J.; Steyaert, J.; Chevigne, A. Mutational analysis of the extracellu- lar disulphide bridges of the atypical chemokine receptor ACKR3 / CXCR7 uncovers multi- ple binding and activation modes for its chemokine and endogenous non-chemokine ago- nists. Biochem. Pharmacol. 2018, 153, 299-309). In short: 5 x 10E6 HEK293T cells were seeded in 10-cm culture dishes and 24 h later co-transfected with pNBe vectors encoding human ACKR3 or CXCR4 receptors C-terminally fused to SmBiT and fi-Arrestin-l N-ter- minally fused to LgBiT. After 24 h, transfection cells were harvested, incubated for 15 minutes at 37 °C with 200-fold diluted Nano-Gio Live Cell substrate, and distributed into white 96-well plates (5 x 104 cells per well). The prepared cells were then treated with compounds at concentrations ranging from 0.3 nM to 100 pM. Induction of fi-Arrestin re- cruitment to receptors was evaluated by measuring bioluminescence with a Mithras LB940 luminometer (Berthold Technologies). For determination of a compound's efficacyand concentration-response curves, the signal recorded was compared to values for CXCL12 at 300 nM considered as full agonist reference ligand (Emax = 100 %).

[0153] All curves were fitted to data points generated from the mean of at least three independent experiments. Results with values of p < 0.05 were considered statisti- cally significant.

[0154] Flow Cytometry Assay. The inhibition of platelet degranulation was de- termined via flow cytometry experiments. Platelets were treated with collagen-related pep- tide (CRP-XL, CambCol Laboratories, Cambridge, UK) and the platelets' activation state was determined (Geue, S.; Aurbach, K.; Manke, M.-C.; Manukjan, G.; Munzer, P.; Ste- gner, D.; Brahler, C.; Walker-Allgaier, B.; Marklin, M.; Borst, C. E.; Quintanilla-Fend, L.; Rath, D.; Geisler, T.; Salih, H. R.; Seizer, P.; Lang, F.; Nieswandt, B.; Gawaz, M.; Schulze, H.; Pleines, I.; Borst, O. Pivotal role of pdk1 in megakaryocyte cytoskeletal dy- namics and polarization during platelet biogenesis. Blood 2019, 134, 1847-1858; and Malehmir, M.; Pfister, D.; Gallage, S.; Szydlowska, M.; Inverse, D.; Kotsiliti, E.; Leone, V.; Peiseler, M.; Surewaard, B. G. J.; Rath, D.; Ali, A.; Wolf, M. J.; Drescher, H.; Healy, M. E.; Dauch, D.; Kroy, D.; Krenkel, O.; Kohlhepp, M.; Engleitner, T.; Olkus, A.; Sijmonsma, T.; Volz, J.; Deppermann, C.; Stegner, D.; Helbling, P.; Nombela-Arrieta, C.; Rafiei, A.; Hinterleitner, M.; Rail, M.; Baku, F.; Borst, O.; Wilson, C. L.; Leslie, J.; O’Connor, T.; Wes- ton, C. J.; Chauhan, A.; Adams, D. H.; Sheriff, L.; Teijeiro, A.; Prinz, M.; Bogeska, R.; An- stee, N.; Bongers, M. N.; Notohamiprodjo, M.; Geisler, T.; Withers, D. J.; Ware, J.; Mann, D. A.; Augustin, H. G.; Vegiopoulos, A.; Milsom, M. D.; Rose, A. J.; Lalor, P. F.; Llovet, J. M.; Pinyol, R.; Tacke, F.; Rad, R.; Matter, M.; Djouder, N.; Kubes, P.; Knolle, P. A.; Unger, K.; Zender, L.; Nieswandt, B.; Gawaz, M.; Weber, A.; Heikenwalder, M. Platelet gpibo is a mediator and potential interventional target for nash and subsequent liver cancer. Nat. Med. 2019, 25, 641-655). Briefly, PRP was isolated from peripheral human blood col- lected in citrate-phosphate-dextrose solution with adenine (CPDA) and diluted with phos- phate-buffered saline (PBS) (Sigma Aldrich Co., Ltd., St. Luis, Missouri, USA) supple- mented with CaCh and MgCh. PRP (106 platelets / sample) was preincubated with the re- spective compound (100 juM) for 15 min. Samples were treated with 1 pg / ml CRP-XL (CambCol Laboratories, Cambridge, UK) for 30 min at room temperature in the presence of the respective fluorochrome-conjugated antibody against P-Selectin (CD62P-FITC;Beckman Coulter, Brea, CA, USA). Subsequently, samples were fixed in 0.5% paraform- aldehyde and analyzed on a FACS-Calibur flow cytometer (FACS-Caliber flow cytometer, Becton-Dickinson, East Rutherford, NJ, USA). Mean fluorescence intensity (MFI) was used as a quantitative measurement of platelet surface expression.

[0155] Cell Viability Assay. RealTime-Glo™ MT Cell Viability Assay (Promega Corporation, Madison, Wl, USA) was performed using THP1 cells and HEK293 cells as indicated in the manufacturer's manual to measure a compound's cytotoxicity on cells. In brief, in a white solid-bottom 96-well plate cells (5x103 / well) were seeded and incubated with the respective compounds diluted in DMEM (Gibco, Carlsbad, CA, USA). After cell seeding viability reagent is added. Subsequently, cells were incubated with the compound and viability reagent containing medium at 37 °C, 5% CO2 for 72 h. The luminescence signal was determined after 1 , 24, 48, and 72 hours on a GloMaxO-Multi Detection Sys- tem plate reader (Promega Corporation, Madison, Wl, USA).

[0156] Metabolic Stability Assay. Pooled liver microsomes from mice (male) and humans (male) were purchased from Sekisui XenoTech, LLC, Kansas City, KS, USA. Metabolic stability assays were performed in the presence of an NADPH-regenerating system consisting of 5 mM glucose-6-phosphate, 5 U / mL glucose-6-phosphate dehydro- genase, and 1 mM NADP+. Liver microsomes (20 mg / mL), NADPH-regenerating system, and 4 mM MgCI26 H2O in 0.1 M TRIS-HCl-buffer (pH 7.4) were preincubated for 5 min at 37 °C and 750 rpm on a shaker. The reaction was started by adding the preheated com- pound at 10 mM resulting in a final concentration of 0.1 mM. The reaction was quenched at selected time points (0, 10, 20, 30, 60, and 120 min) by pipetting 100 / JL of internal standard (ketoprofen) in acetonitrile at concentrations of 600 / JM (compound 26), 800 pM (compound 27), and 450 / JM (compound 35), respectively. The samples were vortexed for 30 s and centrifuged (21910 relative centrifugal force, 4 °C, 20 min). The supernatant was used directly for LC-MS analysis.

[0157] All compound incubations were conducted at least in triplicates. Addi- tionally, a negative control containing BSA (20 mg / mL) instead of liver microsomes and apositive control using Verapamil instead of the compound was performed. A limit of 1 % or- ganic solvent during incubation was not exceeded. Sample separation and detection were performed on an Alliance 2695 Separations Module HPLC system (Waters Corporation, Milford, MA, USA) equipped with a Phenomenex Kinetex 2.6 pm XB-C18 100 A 50 x 3 mm column (Phenomenex Inc., Torrance, CA, USA) coupled to an Alliance 2996 Photodiode Array Detector and a MICROMASS QUATTRO micro API mass spectrometer (both Wafers Corporation, Milford, MA, USA) using electrospray ionization in positive mode. Mo- bile phase A: 90% water, 10% acetonitrile, and additionally 0.1 % formic acid (v / v), mobile phase B: 100% acetonitrile with additional 0.1 % formic acid (v / v). The gradient was set to 0-2.5 min 0% B, 2.5-10 min from 0 to 40% B, 10-12 min 40% B, 12-12.01 min from 40 to 0% B, 12.01-17 min 0% B at a flow rate of 0.7 mL / min. Samples were maintained at 10 °C, the column temperature was set to 20 °C with an injection volume of 5 juL. Spray, cone, extractor, and RF lens voltages were at 4 kV, 30 V, 8 V, and 2 V, respectively. The source and desolvation temperatures were set to 120 °C and 350 °C, respectively, and the desolvation gas flow was set to 750 L / h. Data analysis was conducted using Mass- Lynx 4.1 software (Waters Corporation, Milford, MA, USA).

[0158] Solubility Assay. A 100 mL flask with phosphate-buffered saline was pre- pared from NaCI, KCI, NapHPO^ KH2PO4, and distilled water. The buffer was adjusted to pH 7.4 with HCL Afterwards, 10mM stock solutions of compounds in DMSO were pre- pared. 10 pL compound stock solution was added to 990 pL PBS in Eppendorf tubes. As a reference, 10 pL compound stock solution was added to 990 pL HPLC-grade MeOH in Eppendorf tubes. All tubes were centrifuged (16000 relative centrifugal force, 4 °C, 20 min). Subsequently, 600 pL supernatant was extracted carefully and filled into HPLC vials. Compound area under the curve (AUG) was determined by RP-HPLC using an Agilent 1100 Series LC with a Phenomenex Luna C8 analytical column (150 x 4.6 mm, 5 pm) and detected by a UV DAD detector at 254 nm and 230 nm wavelength. Compounds solubility was calculated by AUC of compound in PBS divided by AUC of reference solution multi- plied by concentration of the compound in solution.

[0159] Aggregation experiments. For the light transmission aggregation experi- ments, citrate anticoagulated blood from healthy donors was used. To obtain platelet-rich plasma, whole blood was centrifuged at 210 x g for 20 min at room temperature. 1 x 10A8platelets were preincubated with 100 pM ACKR3 agonist for 15 min at 37°C. Subse- quently, platelets were activated with 2.5 pM ADP and aggregation was analyzed for 5 min at 1 ,000 rpm and 37°C using a light transmission aggregometer (Aggregometer 490- X; Chrono-Log Corp., Havertown, Pennsylvania, United States). Maximum platelet aggre- gation and the area under the curve were quantified using Aggrolink8 software (Chrono- Log Corp., Havertown, Pennsylvania, United States).Synthesis of intermediates

[0160] / V1-benzyl-A / 1-methylpropane-1 ,3-diamine dihydrochloride (1a). 0.33 g (1 .2 mmol) 1 b was dissolved in 6 mL (23.7 mmol) 4M HCI in 1 ,4-dioxane. The mixture was stirred at room temperature for 3 h. The formed HCI-salt of the product was filtered off by suction filtration and dried under reduced pressure obtaining a yellow solid in 72 % yield (0.215 g, 0.86 mmol). The product was used without further purification.1H NMR (400 MHz, DMSO) δ 11.24 (s, 1 H), 8.31 (s, 3H), 7.69 - 7.60 (m, 2H), 7.48 - 7.41 (m, 3H), 4.41 - 4.18 (m, J = 18.8, 13.0, 5.2 Hz, 2H), 3.24 - 3.03 (m, 2H), 2.94 - 2.79 (m, 2H), 2.61 (d, J = 4.9 Hz, 3H), 2.10 (quint, 2H).13C NMR (101 MHz, DMSO) δ 131.50, 129.87, 129.46, 128.76, 58.15, 51.69, 38.50, 36.24, 21.61. TLC-MS (ESI+): calcd. m / z 178.15 for CnH18N2. Found 179.2 [M+H]+.

[0161] / V1-(4-methoxybenzyl)- / V-methylpropane-1 ,3-diamine dihydrochloride (18a). 0.315 g (1.02 mmol) 18b was dissolved in 5.1 mL (20.4 mmol) 4M HCI in 1 ,4-diox- ane. The mixture was stirred at room temperature for 3 h. The formed product was filtered off by suction filtration and dried under reduced pressure obtaining a white solid in 90 % yield (0.258 g, 0.92 mmol). The product was used without further purification.1H NMR (400 MHz, DMSO) δ 11.14 (s, 1 H), 8.34 (s, 3H), 7.56 (d, J = 8.7 Hz, 2H), 6.98 (d, J = 8.7 Hz, 2H), 4.34 - 4.10 (m, J = 18.2, 13.0, 4.7 Hz, 2H), 3.77 (s, 3H), 3.24 - 2.96 (m, 2H), 2.95 - 2.77 (m, J = 12.1, 6.4 Hz, 2H), 2.58 (d, J = 4.4 Hz, 3H), 2.10 (quint, 2H).13C NMR (101 MHz, DMSO) δ 159.99, 133.02, 121.56, 114.06, 57.64, 55.23, 51.32, 38.21 , 36.22, 21.61. TLC-MS (ESI+): calcd. m / z 208.16 for C12H20N2O. Found 209.1 [M+H]+.

[0162] / V1-(4-bromobenzyl)- / V1-methylpropane-1,3-diamine dihydrochloride (19a). 0.354 g (0.99 mmol) 19b was dissolved in 5 mL (19.8 mmol) 4M HCI in 1 ,4-dioxane. The mixture was stirred at room temperature for 3 h. The formed product was filtered off by suction filtration and dried under reduced pressure obtaining a white solid in 98 % yield (0.32 g, 0.97 mmol). The product was used without further purification.1H NMR (400 MHz, DMSO) δ 11.38 (s, 1 H), 8.30 (s, 3H), 7.71 - 7.58 (m, 4H), 4.42 - 4.18 (m, J = 18.7, 13.1 , 5.1 Hz, 2H), 3.27 - 2.98 (m, 2H), 2.94 - 2.77 (m, 2H), 2.61 (d, J = 4.8 Hz, 3H), 2.10 (quint, 2H).13C NMR (101 MHz, DMSO) δ 133.73, 131.68, 129.26, 123.10, 57.30, 51.61 , 38.47, 36.19, 21.57. TLC-MS (ESI+): calcd. m / z 256.06 for CnHi7BrN2. Found 257.0 / 259.0 [M+H]+.

[0163] A / 1-(4-fluorobenzyl)-A / 1-methylpropane-1,3-diamine dihydrochloride (20a). 0.313 g (1.06 mmol) 20b was dissolved in 5.3 mL (21.1 mmol) 4M HCI in 1 ,4-diox- ane. The mixture was stirred at room temperature for 3 h. The formed HCI-salt of the product was filtered off by suction filtration and dried under reduced pressure obtaining a white solid. The crude product was used without further purification.

[0164] / V1-(2-fluorobenzyl)- / V-methylpropane-l ,3-diamine dihydrochloride (21a). 0.43 g (1.45 mmol) 21b was dissolved in 7.25 mL (29 mmol) 4M HCI in 1 ,4-dioxane. The mixture was stirred at room temperature for 3 h. The formed product was filtered off by suction filtration and dried under reduced pressure obtaining a white semi-solid in 86 % yield (0.336 g, 1.25 mmol). The product was used without further purification.1H NMR (400 MHz, DMSO) δ 11.32 (s, 1 H), 8.34 (s, 3H), 7.83 (td, J = 7.6, 1.4 Hz, 1 H), 7.65 - 7.44 (m, J = 7.3, 1.6 Hz, 1 H), 7.39 - 7.19 (m, 2H), 4.45 - 4.20 (m, J = 18.9, 13.4, 4.6 Hz, 2H), 3.33 - 3.06 (m, 2H), 2.98 - 2.77 (m, 2H), 2.65 (d, J = 4.6 Hz, 3H), 2.23 - 2.03 (m, 2H).13C NMR (101 MHz, DMSO) δ 161.09, 134.10, 132.29, 124.85, 116.85, 115.85, 51.84, 51.22, 38.68, 36.17, 21.75. TLC-MS (ESI+): calcd. m / z 196.14 for CHHI7FN2. Found 197.1 [M+H]+.

[0165] A / 1-(3-fluorobenzyl)-A / 1-methylpropane-1,3-diamine dihydrochloride (22a). 0.35 g (1.18 mmol) 22b was dissolved in 5.9 mL (23.6 mmol) 4M HCI in 1,4-diox- ane. The mixture was stirred at room temperature for 3 h. The formed product was filtered off by suction filtration and dried under reduced pressure obtaining a white solid in 97 %yield (0.307 g, 1.14 mmol). The product was used without further purification.1H NMR (400 MHz, DMSO) δ 11.40 (s, 1 H), 8.29 (s, 3H), 7.61 (d, J = 8.4 Hz, 1 H), 7.55 - 7.43 (m, 2H), 7.39 - 7.23 (m, J = 9.0, 5.9, 3.7 Hz, 1 H), 4.51 - 4.18 (m, 2H), 3.29 - 2.99 (m, 2H), 2.98 - 2.76 (m, 2H), 2.62 (s, 3H), 2.11 (quint, 2H).13C NMR (101 MHz, DMSO) δ 161.90, 132.50, 130.79, 127.68, 118.27, 116.42, 57.44, 51.80, 38.57, 36.21 , 21.60. TLC-MS (ESI+): calcd. m / z 196.14 for C11H17FN2. Found 197.1 [M+H]+.

[0166] / V1-benzyl-A / 1-ethylpropane-1 ,3-diamine dihydrochloride (23a). 0.28 g (0.96 mmol) 23b was dissolved in 4.8 mL (19.2 mmol) 4M HCI in 1 ,4-dioxane. The mixture was stirred at room temperature for 3 h. The formed HCI-salt of the product was filtered off by suction filtration and dried under reduced pressure obtaining a white solid. The crude product was used without further purification.

[0167] / V1-benzyl-A / 1-isopropylpropane-1 ,3-diamine dihydrochloride (24a). 0.205 g (0.67 mmol) 24b was dissolved in 3.34 mL (13.4 mmol) 4M HCI in 1 ,4-dioxane. The mix- ture was stirred at room temperature for 1 h. The formed product was filtered off by suc- tion filtration and dried under reduced pressure. The product was used without further pu- rification.

[0168] / V1-benzyl-A / 1-cyclopropylpropane- 1 ,3-diamine dihydrochloride (25a). 0.357 g (1.17 mmol) 25b was dissolved in 5.85 mL (23.45 mmol) 4M HCI in 1 ,4-dioxane. The mixture was stirred at room temperature for 1 h. The formed product was filtered off by suction filtration and dried under reduced pressure. The product was used without fur- ther purification. TLC-MS (ESI+): calcd. m / z 204.16 for C13H20N2. Found 205.2 [M+H]+.

[0169] A / 1-benzyl-A / 1-propylpropane-1,3-diamine dihydrochloride (26a). 0.37 g (1.21 mmol) 26b was dissolved in 6.04 mL (24.15 mmol) 4M HCI in 1,4-dioxane. The mix- ture was stirred at room temperature for 1 h. The formed product was filtered off by suc- tion filtration and dried under reduced pressure obtaining a colorless oil. The product was used without further purification. TLC-MS (ESI+): calcd. m / z 206.18 for C13H22N2. Found 207.2 [M+H]+.

[0170] / V1-benzyl-A / 1-butylpropane-1 ,3-diamine dihydrochloride (27a). 0.375 g (1.17 mmol) 27b was dissolved in 5.85 mL (23.4 mmol) 4M HCI in 1 ,4-dioxane. The mix- ture was stirred at room temperature for 1 h. The formed product was filtered off by suc- tion filtration and dried under reduced pressure. The product was used without further pu- rification. TLC-MS (ESI+): calcd. m / z 220.19 for C14H24N2. Found 221.2 [M+H]+.

[0171] 3-((3-aminopropyl)(benzyl)amino)propan-1-ol dihydrochloride (28a).0.388 g (1.2 mmol) 28b was dissolved in 6 mL (24 mmol) 4M HCI in 1 ,4-dioxane. The mix- ture was stirred at room temperature overnight. The formed product was dried under re- duced pressure obtaining a yellow oil in 99 % yield (0.353 g, 1.2 mmol). The product was used without further purification.1H NMR (400 MHz, DMSO) δ 11.09 (s, 1 H), 8.24 (s, 3H), 7.75 - 7.61 (m, 2H), 7.49 - 7.39 (m, 3H), 4.38 - 4.24 (m, 2H), 3.49 - 3.36 (m, 2H), 3.22 - 2.79 (m, 7H), 2.20 - 1.97 (m, 2H), 2.00 - 1.81 (m, 2H).13C NMR (101 MHz, DMSO) δ 131.39, 129.83, 129.41 , 128.75, 57.90, 55.81 , 49.25, 48.85, 36.25, 25.76, 21.16. TLC-MS (ESI+): calcd. m / z 222.17 for C13H22N2O. Found 223.1 [M+H]+.

[0172] Af-benzyl-Af-phenethylpropane-I .S-diamine dihydrochloride (29a).0.178 g (0.48 mmol) 29b was dissolved in 2.4 mL (9.66 mmol) 4M HCI in 1,4-dioxane. The mixture was stirred at room temperature overnight. The formed product was filtered off by suction filtration and dried under reduced pressure obtaining a pale-brown solid in 99 % yield (0.164 g, 0.48 mmol). The product was used without further purification.13C NMR (101 MHz, CDCI3) δ 136.27, 131.57, 130.01 , 129.39, 129.05, 128.92, 128.84, 127.14, 56.98, 52.71 , 51.21 , 37.89, 29.72, 22.35. TLC-MS (ESI+): calcd. m / z 268.19 for C18H24N2. Found 269.1 [M+H]+. HPLC fR= 1.907 min.

[0173] / V-benzyl-Af-^-phenylpropylJpropane-I .S-diamine dihydrochloride (30a). 0.184 g (0.48 mmol) 30b was dissolved in 2.4 mL (9.6 mmol) 4M HCI in 1 ,4-diox- ane. The mixture was stirred at room temperature overnight. The formed product was fil- tered off by suction filtration and dried under reduced pressure obtaining a pale-brown solid in 99 % yield (0.168 g, 0.47 mmol). The product was used without further purification.1H NMR (400 MHz, DMSO) 5 8.29 (s, 3H), 7.65 (dd, J = 7.3, 2.2 Hz, 2H), 7.48 - 7.36 (m, 3H), 7.35 - 7.10 (m, 6H), 4.39 - 4.22 (m, 2H), 3.24 - 3.07 (m, 2H), 3.03 - 2.90 (m, 2H), 2.90 - 2.79 (m, 2H), 2.64 - 2.54 (m, 2H), 2.26 - 1 .95 (m, 4H).13C NMR (101 MHz,DMSO) δ 140.36, 131.38, 129.74, 129.34, 128.70, 128.32, 128.28, 126.06, 55.65, 50.66, 48.95, 36.23, 31.98, 24.01 , 21.22. TLC-MS (ESI+): calcd. m / z 282.21 for C19H26N2. Found 283.3 [M+H]+. HPLC tR= 2.399 min.

[0174] / V-(3-(benzyl(ethyl)amino)propyl)-5-bromothiophene-2-carboxamide (31a). 0.112 g (0.54 mmol) 5-bromothiophene-2-carboxylic acid was dissolved in 2.2 mL dry DMF and 0.227 g (0.6 mmol) HATU was slowly added. After 15 min of continuous stir- ring, 0.144 g (0.54 mmol) 23a and 0.43 mL (2.44 mmol) DIPEA was added to the mixture. The mixture was allowed to stir at room temperature overnight. After complete reaction, the mixture was diluted with DCM, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dry- ness. The mixture was purified via flash chromatography (SiO2; DCM / MeOH 1 - 4 %). The crude product was used without further purification. TLC-MS (ESI+): calcd. m / z 380.06 for Ci7H2iBrN2OS. Found 381.1 [M+H]+.

[0175] 5-bromo-A / -(3-(ethyl(4-fluorobenzyl)amino)propyl)thiophene-2-carbox- amide (32a). 0.088 g (0.42 mmol) 5-bromothiophene-2-carboxylic acid was dissolved in 1.7 mL dry DMF and 0.177 g (0.47 mmol) HATU was slowly added. After 15 min of contin- uous stirring, 0.12 g (0.42 mmol) 32b and 0.33 mL (1.91 mmol) DIPEA was added to the mixture. The mixture was allowed to stir at room temperature overnight. After complete re- action, the mixture was diluted with DCM, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The mixture was purified via flash chromatography (SiO2; DCM / MeOH 1 - 4 %) obtaining a white solid. The crude product was used without further purification. TLC-MS (ESI+): calcd. m / z 398.05 for Ci7H2oBrFN2OS. Found 399.1 [M+H]+.

[0176] / V-(3-aminopropyl)-5-phenylthiophene-2-carboxamide hydrochloride (34a). 0.6 g (1.66 mmol) 33 was dissolved in 8.3 mL (33.3 mmol) 4M HCI in 1,4-dioxane. The mixture was stirred at room temperature overnight. The formed product was filtered off by suction filtration and dried under reduced pressure obtaining a pale-yellow solid in 99 % yield (0.486 g, 1.64 mmol). The product was used without further purification.1H NMR (400 MHz, DMSO) δ 8.92 (t, J = 5.6 Hz, 1H), 8.10 (s, 3H), 7.88 (d, J = 3.9 Hz, 1H), 7.74 - 7.64 (m, 2H), 7.54 (d, J = 3.9 Hz, 1 H), 7.44 (dd, J = 10.3, 4.7 Hz, 2H), 7.39 - 7.31(m, 1H), 3.32 (q, J = 6.4 Hz, 2H), 2.89 - 2.77 (m, 2H), 1.84 (quint, 2H).13C NMR (101 MHz, DMSO) δ 161.19, 147.33, 138.79, 133.12, 129.36, 129.24, 128.48, 125.64, 124.29, 39.52, 36.68, 36.10, 27.26. TLC-MS (ESI+): calcd. m / z 260.1 for CI4HI6N2OS. Found 261 .1 [M+H]+. HPLC tR= 3.973 min.

[0177] 3-(3,4-dihydroisoquinolin-2(1 / 7)-yl)propan-1 -amine dihydrochloride (35a). 0.61 g (2.1 mmol) 35b was dissolved in 10.5 mL (42 mmol) 4M HCI in 1 ,4-dioxane. The mixture was stirred at room temperature for 1 h. The formed product was filtered off by suction filtration and dried under reduced pressure. The product was used without further purification. TLC-MS (ESI+): calcd. m / z 190.15 for CI2HI8N2. Found 191.2 [M+H]+.

[0178] / V-(3-(((3-aminopropyl)(methyl)amino)methyl)phenyl)-4-fluorobenzamide (36a). 0.506 g (1.22 mmol) 36b was dissolved in 6.1 mL (24.4 mmol) 4M HCI in 1 ,4-diox- ane. The mixture was stirred at room temperature for 3 h. After complete reaction, the mixture was diluted with DCM, washed with NH4CI (3x 20 mL), NaHCO3(3x 20 mL) and brine (3x 20 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness obtaining a yellow oil. The crude product was used without further purification. TLC-MS (ESI+): calcd. m / z 315.17 for CI8H22FN3O. Found 316.2 [M+H]+.

[0179] 1-(3-aminopropyl)-A / -(tert-butyl)piperidine-4-carboxamide dihydrochloride (37a). 0.36 g (1.27 mmol) 37b was dissolved in 6.3 mL (25.3 mmol) 4M HCI in 1,4-diox- ane. The mixture was stirred at room temperature for 3 h. The formed HCI-salt of the product was filtered off by suction filtration and dried under reduced pressure obtaining a white solid in 77 % yield (0.306 g, 0.98 mmol). The product was used without further purifi- cation.1H NMR (400 MHz, DMSO) δ 3.45 (d, J = 12.4 Hz, 2H), 3.16 (dd, J = 12.8, 7.7 Hz, 3H), 2.89 - 2.77 (m, 4H), 2.39 - 2.29 (m, 1 H), 2.11 - 1.78 (m, 8H), 1.25 (s, 2H), 1.22 (d, J = 4.8 Hz, 9H).13C NMR (101 MHz, DMSO) δ 172.3, 52.9, 51.1, 49.9, 48.7, 36.3, 28.5, 25.7, 23.5, 21.4.

[0180] (1-benzylpiperidin-3-yl)methanamine hydrochloride (39a). 0.165 g (0.54 mmol) 39b was dissolved in 2.71 mL (10.8 mmol) 4M HCI in 1,4-dioxane. The mixture wasstirred at room temperature overnight. The formed product was filtered off by suction filtra- tion and dried under reduced pressure obtaining a white solid in 99 % yield (0.163 g, 0.53 mmol). The product was used without further purification.1H NMR (400 MHz, DMSO) δ 8.55 - 8.01 (m, 3H), 7.76 - 7.59 (m, 2H), 7.53 - 7.17 (m, 3H), 4.45 - 4.09 (m, 2H), 3.49 - 3.23 (m, 2H), 3.11 - 2.57 (m, 4H), 2.46 - 2.28 (m, 1 H), 2.02 - 1.69 (m, 3H), 1.19 - 1.00 (m, 1H).13C NMR (101 MHz, DMSO) δ 131.72, 129.37, 129.32, 128.62, 59.39, 53.13, 51.15, 41.12, 31.82, 25.56, 21.24. TLC-MS (ESI+): calcd. m / z 204.16 for C13H20N2. Found 205.0 [M+H]+. HPLC tR= 1.102 min.

[0181] N-(3-(( 1 ,4-diazepan-1 -yl)methyl)phenyl)-4-fluorobenzamide hydrochlo- ride (41a). 0.5 g (1.17 mmol) 41b was dissolved in 5.9 ml_ (23.4 mmol) 4M HCI in 1 ,4-di- oxane. The mixture was stirred at room temperature for 3 h. The formed HCI-salt of the product was filtered off by suction filtration and dried under reduced pressure obtaining a white solid in 92 % yield (0.392 g, 1.08 mmol). The product was used without further purifi- cation.1H NMR (400 MHz, DMSO) δ 10.53 (s, 1 H), 9.91 (s, J = 37.5 Hz, 1 H), 9.62 (s, 1 H), 8.12 - 8.06 (m, 2H), 8.03 (s, 1 H), 7.81 - 7.73 (m, J = 8.1 Hz, 1 H), 7.52 - 7.34 (m, 4H), 3.75 - 3.56 (m, J = 25.4, 14.7 Hz, 4H), 3.48 - 3.10 (m, 4H), 2.54 (s, 2H), 2.30 - 2.09 (m, 2H).13C NMR (101 MHz, DMSO) δ 165.38, 164.51 , 162.91 , 139.39, 131.06, 130.46, 130.23, 129.16, 126.66, 123.38, 121.64, 115.47, 66.35, 59.14, 52.39, 48.83, 43.72, 40.43, 20.34. TLC-MS (ESI+): calcd. m / z 327.17 for C19H22FN3O. Found 328.2 [M+H]+.

[0182] (3-nitrophenyl)methanamine dihydrochloride (42a). 1 .13 g (4 mmol) 42b was dissolved in 20 mL EtOH and 0.83 mL (20 mmol) hydrazine hydrate (80% solution in water) was slowly added. The mixture was heated to 60 °C and stirred overnight. After complete consumption of the starting material, the formed precipitate was filtered off. The filtrate was concentrated and redissolved in DCM. To the suspension HCI in 1,4-dioxane was added and the formed solid was filtered off and washed multiple times with EtOAc. The product was dried under reduced pressure obtaining a brown solid.1H NMR (400 MHz, DMSO) δ 8.76 (s, 3H), 8.46 (t, J = 1.8 Hz, 1 H), 8.23 (d, J = 8.2, 1.5 Hz, 1 H), 8.01 (d, J = 7.7 Hz, 1 H), 7.71 (t, J = 8.0 Hz, 1 H), 4.18 (q , J = 5.8 Hz, 2H).13C NMR (101 MHz, DMSO) δ 147.65, 136.33, 135.99, 130.05, 124.01, 123.25, 41.26.

[0183] / V-(3-aminobenzyl)-5-phenylthiophene-2-carboxamide (43a). 0.224 g (0.66 mmol) 42 was dissolved in 4 mL EtOH and the solution was cooled to 0 °C. 0.04 g 10% Pd / C was added under a nitrogen atmosphere to the solution. The flask was repeat- edly evacuated and flushed with H2 gas and the H2 gas was allowed to bubble in the sus- pension for 15 min. The mixture was stirred overnight at room temperature. After complete reaction, the flask was purged with N2, and the crude reaction mixture was filtered through a short plug of celite. The reaction vessel and celite were rinsed with EtOH. The combined filtrates were concentrated under reduced pressure and the residue was dried under high vac overnight obtaining a brown solid. The crude product was used without fur- ther purification. TLC-MS (ESI+): calcd. m / z 308.10 for Ci8Hi6N2OS. Found 309.1 [M+H]+.

[0184] ferf-butyl 4-(3-aminopropyl)piperazine-1 -carboxylate (46a). 4.5 g (12.2 mmol) 46b was dissolved in 61 mL EtOH and 2.52 mL (61 mmol) hydrazine hydrate (80% solution in water) was slowly added. The mixture was heated to 60 °C and stirred over- night. After complete consumption of the starting material, the formed precipitate was fil- tered off. The filtrate was concentrated and redissolved in DCM. The solution was washed with water (3x 30 mL) and brine (3x 30 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness obtaining a yellow oil in 77 % yield (2.286 g, 9.4 mmol). The product was used without further purification.1H NMR (400 MHz, CDCI3) δ 3.45 - 3.37 (m, 4H), 2.73 (t, J = 6.8 Hz, 2H), 2.45 - 2.30 (m, 6H), 1.62 (quint, 2H), 1.44 (s, 9H), 1.38 (s, J = 13.9 Hz, 2H).13C NMR (101 MHz, CDCI3) δ 154.9, 79.7, 56.6, 53.2, 40.8, 30.6, 28.5.

[0185] / V-benzylpiperidine-4-carboxamide hydrochloride (48a). 0.64 g (2 mmol) 48b was dissolved in 10 mL (40 mmol) 4M HCI in 1,4-dioxane. The mixture was stirred at room temperature for 3 h. The formed HCI-salt of the product was filtered off by suction filtration and dried under reduced pressure obtaining a white solid in 52 % yield (0.266 g, 1.04 mmol). The product was used without further purification.1H NMR (400 MHz, DMSO) 5 8.89 (d, J = 7.3 Hz, 1 H), 8.55 (t, J = 5.9 Hz, 1 H), 7.37 - 7.17 (m, 5H), 4.25 (d, J = 5.9 Hz, 2H), 3.21 (t, J = 19.1 Hz, 2H), 2.93 - 2.74 (m, 2H), 2.50 - 2.44 (m, J = 7.5, 3.4 Hz, 1H), 1.97 - 1.67 (m, 4H).13C NMR (101 MHz, DMSO) δ 173.1, 139.6, 128.3, 127.1, 126.8, 42.3, 41.9, 25.2.

[0186] tert-butyl (3-(benzyl(methyl)amino)propyl)carbamate (1 b). 0.97 mL (7.56 mmol) / V-methyl-1-phenylmethanamine, 1.8 g (7.56 mmol) tert-butyl (3-bromopropyl)car- bamate, 4.93 g (15.12 mmol) cesium carbonate, and 0.627 g (3.78 mmol) potassium io- dide were added in a flask with 30.2 mL acetone. The mixture stirred at room temperature for 72 h. After complete reaction, the formed precipitate was filtered off, the filtrate was concentrated and redissolved in DCM. The solution was washed with water (3x 30 mL) and brine (3x 30 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The crude product was purified via flash chromatography (SiO2; DCM / MeOH 0 - 5 %) obtaining a yellow oil in 53 % yield (1.12 g, 4.08 mmol). TLC-MS (ESI+): calcd. m / z 278.20 for CI6H26N2O2. Found 301 .2 [M+Na]+.

[0187] tert-butyl (3-((4-methoxybenzyl)(methyl)amino)propyl)carbamate (18b). 0.31 mL (2.1 mmol) 1-(4-methoxyphenyl)-N-methylmethanamine, 0.5 g (2.1 mmol) tert- butyl (3-bromopropyl)carbamate, 1.37 g (4.2 mmol) cesium carbonate, and 0.174 g (1.05 mmol) potassium iodide were added in a flask with 8.4 mL acetone. The mixture stirred at room temperature for 72 h. After complete reaction, the formed precipitate was filtered off, the filtrate was concentrated and redissolved in DCM. The solution was washed with wa- ter (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The crude product was purified via flash chromatography (SiO2; DCM / MeOH 1 - 3 %) obtaining a yellow oil in 49 % yield (0.315 g, 1 .03 mmol).1H NMR (400 MHz, CDCI3) δ 7.25 - 7.15 (m, 2H), 6.90 - 6.79 (m, 2H), 5.58 (s, 1 H), 3.79 (s, 3H), 3.41 (s, 2H), 3.18 (q, J = 11.6, 5.7 Hz, 2H), 2.43 (t, J = 6.3 Hz, 2H), 2.15 (s, 3H), 1.67 (quint, J = 6.3 Hz, 2H), 1.44 (s, 9H).13C NMR (101 MHz, CDCI3) δ 158.82, 156.25, 130.90, 130.29, 130.29, 113.77, 113.77, 78.85, 62.05, 55.97, 55.35, 42.03, 40.18, 28.61 , 28.61 , 28.61 , 26.57. TLC-MS (ESI+): calcd. m / z 308.21 for Ci7H28N2O3. Found 331.2 [M+Na]+.

[0188] tert-butyl (3-((4-bromobenzyl)(methyl)amino)propyl)carbamate (19b). 0.42 mL (2.1 mmol) 1-(4-bromophenyl)- / V-methylmethanamine, 0.5 g (2.1 mmol) tert-butyl (3-bromopropyl)carbamate, 1.37 g (4.2 mmol) cesium carbonate, and 0.174 g (1.05 mmol) potassium iodide were added in a flask with 8.4 mL acetone. The mixture stirred at room temperature for 72 h. After complete reaction, the formed precipitate was filtered off, the filtrate was concentrated and redissolved in DCM. The solution was washed with water(3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The crude product was purified via flash chromatog- raphy (SiCk; PE / EtOAc 10 - 40 %) obtaining a yellow oil in 47 % yield (0.354 g, 0.99 mmol).1H NMR (400 MHz, CDCI3) δ 7.46 - 7.38 (m, 2H), 7.22 - 7.16 (m, J = 8.4 Hz, 2H), 5.43 (s, 1 H), 3.42 (s, 2H), 3.18 (q, J = 11.6, 5.7 Hz, 2H), 2.43 (t, J = 6.4 Hz, 2H), 2.15 (s, 3H), 1.67 (quint, J = 6.4 Hz, 2H), 1.44 (s, 9H).13C NMR (101 MHz, CDCI3) δ 156.19, 138.11 , 131.52, 131.52, 130.74, 130.74, 120.96, 78.97, 62.05, 56.07, 42.12, 40.00, 28.61 , 28.61 , 28.61 , 26.73. TLC-MS (ESI+): calcd. m / z 356.11 / 358.11 for Ci6H25BrN2O2. Found 379.1 / 381.1 [M+Na]+.

[0189] tert-butyl (3-((4-fluorobenzyl)(methyl)amino)propyl)carbamate (20b).0.37 g (2.65 mmol) 20c, 0.63 g (2.65 mmol) tert-butyl (3-bromopropyl)carbamate, 1.72 g (5.3 mmol) cesium carbonate, and 0.22 g (1.32 mmol) potassium iodide were added in a flask with 10.6 mL acetone. The mixture stirred at room temperature for 72 h. After com- plete reaction, the formed precipitate was filtered off, the filtrate was concentrated and re- dissolved in DCM. The solution was washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dry- ness obtaining a yellow oil. The crude product was used without further purification.

[0190] tert-butyl (3-((2-fluorobenzyl)(methyl)amino)propyl)carbamate (21b).0.28 mL (2.1 mmol) 1-(2-fluorophenyl)-A / -methylmethanamine, 0.5 g (2.1 mmol) tert-butyl (3-bromopropyl)carbamate, 1.37 g (4.2 mmol) cesium carbonate, and 0.174 g (1.05 mmol) potassium iodide were added in a flask with 8.4 mL acetone. The mixture stirred at room temperature for 72 h. After complete reaction, the formed precipitate was filtered off, the filtrate was concentrated and redissolved in DCM. The solution was washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The crude product was purified via flash chromatog- raphy (SiO?; PE / EtOAc 10 - 40 %) obtaining a yellow oil in 69 % yield (0.429 g, 1.45 mmol).1H NMR (400 MHz, CDCI3) δ 7.41 - 7.32 (m, J = 7.5, 1.5 Hz, 1H), 7.25 - 7.18 (m, J = 7.3, 4.7, 2.0 Hz, 1H), 7.14 - 7.07 (m, J = 7.5, 1.0 Hz, 1H), 7.05 - 6.98 (m, 1H), 5.39 (s, 1H), 3.55 (s, 2H), 3.18 (q, J = 11.8, 5.8 Hz, 2H), 2.47 (t, J = 6.4 Hz, 2H), 2.20 (s, 3H), 1.67 (quint, 2H), 1.44 (s, 9H).13C NMR (101 MHz, CDCI3) δ 161.56, 156.25, 131.51 , 128.91,125.48, 124.05, 115.41 , 78.88, 55.96, 54.91 , 42.02, 39.98, 28.59, 26.81. TLC-MS (ESI+): calcd. m / z 296.19 for CI6H25FN2O2. Found 319.2 [M+Na]+.

[0191] tert-butyl (3-((3-fluorobenzyl)(methyl)amino)propyl)carbamate (22b).0.29 mL (2.1 mmol) 1-(3-fluorophenyl)-A / -methylmethanamine, 0.5 g (2.1 mmol) tert-butyl (3-bromopropyl)carbamate, 1.37 g (4.2 mmol) cesium carbonate, and 0.174 g (1.05 mmol) potassium iodide were added in a flask with 8.4 mL acetone. The mixture stirred at room temperature for 72 h. After complete reaction, the formed precipitate was filtered off, the filtrate was concentrated and redissolved in DCM. The solution was washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The crude product was purified via flash chromatog- raphy (SiO2; PE / EtOAc 10 - 40 %) obtaining a yellow oil in 56 % yield (0.336 g, 1.18 mmol).1H NMR (400 MHz, CDCI3) δ 7.30 - 7.22 (m, 1H), 7.08 (d, J = 7.6 Hz, 1H), 7.06 - 7.01 (m, 1 H), 6.97 - 6.89 (m, J = 8.3, 2.0 Hz, 1 H), 5.45 (s, 1 H), 3.46 (s, 2H), 3.20 (q, J = 11.8, 5.8 Hz, 2H), 2.45 (t, J = 6.3 Hz, 2H), 2.17 (s, 3H), 1.67 (quint, 2H), 1.44 (s, 9H).13C NMR (101 MHz, CDCI3) δ 163.01, 156.23, 141.80, 129.84, 124.54, 115.76, 114.08, 79.01, 62.23, 56.19, 42.16, 40.04, 28.57, 26.74. TLC-MS (ESI+): calcd. m / z 296.19 for CI6H25FN2O2. Found 319.2 [M+Na]+.

[0192] tert-butyl (3-(benzyl(ethyl)amino)propyl)carbamate (23b). 0.31 mL (2.1 mmol) A / -benzylethanamine, 0.5 g (2.1 mmol) tert-butyl (3-bromopropyl)carbamate, 1.37 g (4.2 mmol) cesium carbonate, and 0.174 g (1.05 mmol) potassium iodide were added in a flask with 8.4 mL acetone. The mixture stirred at room temperature for 72 h. After com- plete reaction, the formed precipitate was filtered off, the filtrate was concentrated and re- dissolved in DCM. The solution was washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dry- ness. The crude product was purified via flash chromatography (SiO2; DCM / MeOH 2 - 7 %) obtaining a yellow oil in 46 % yield (0.282 g, 0.97 mmol). TLC-MS (ESI +): calcd. m / z 292.22 for CI7H28N2O2. Found 315.2 [M+Na]+.

[0193] tert-butyl (3-(benzyl(isopropyl)amino)propyl)carbamate (24b). 0.35 mL (2.1 mmol) A / -benzylpropan-2-amine, 0.5 g (2.1 mmol) tert-butyl (3-bromopropyl)carba- mate, 1.37 g (4.2 mmol) cesium carbonate, and 0.35 g (2.1 mmol) potassium iodide wereadded in a flask with 8.4 mL acetone. The mixture was stirred at rt for 72 h. After complete reaction, the mixture was diluted with EtOAc, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The mixture was purified via flash chromatography (SiO2; PE / EtOAc 0 - 30 %). The crude product was used without further purification. TLC-MS (ESI+): calcd. m / z 306.23 for CI8H3ON202. Found 329.2 [M+Na]+.

[0194] tert-butyl (3-(benzyl(cyclopropyl)amino)propyl)carbamate (25b). 0.31 mL (2.1 mmol) / V-benzylcyclopropanamine, 0.5 g (2.1 mmol) tert-butyl (3-bromopropyl)carba- mate, 1.37 g (4.2 mmol) cesium carbonate, and 0.35 g (2.1 mmol) potassium iodide were added in a flask with 8.4 mL acetone. The mixture was stirred at rt for 72 h. After complete reaction, the mixture was diluted with EtOAc, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The mixture was purified via flash chromatography (SiO2; DCM / MeOH 0 - 3 %). The crude product was used without further purification. TLC-MS (ESI+): calcd. m / z 304.22 for CI8H28N2O2. Found 327.2 [M+Na]+.

[0195] tert-butyl (3-(benzyl(propyl)amino)propyl)carbamate (26b). 0.35 mL (2.1 mmol) A / -benzylpropan-1 -amine, 0.5 g (2.1 mmol) tert-butyl (3-bromopropyl)carbamate, 1.37 g (2.1 mmol) cesium carbonate, and 0.174 g (1.05 mmol) potassium iodide were added in a flask with 8.4 mL acetone. The mixture was stirred at rt for 72 h. After complete reaction, the mixture was diluted with EtOAc, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness obtaining a yellow oil. The crude product was used without further purification. TLC-MS (ESI+): calcd. m / z 306.23 for CI8H30N2O2. Found 307.2 [M+H]+.

[0196] tert-butyl (3-(benzyl(butyl)amino)propyl)carbamate (27b). 0.38 mL (2.1 mmol) / V-benzylbutan-1 -amine, 0.5 g (2.1 mmol) tert-butyl (3-bromopropyl)carbamate, 1.37 g (4.2 mmol) cesium carbonate, and 0.35 g (2.1 mmol) potassium iodide were added in a flask with 8.4 mL acetone. The mixture was stirred at rt for 72h. After complete reac- tion, the mixture was diluted with EtOAc, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The mixture was purified via flash chromatography (SiO2; DCM / MeOH 0 - 3 %).The crude product was used without further purification. TLC-MS (ESI+): calcd. m / z 320.25 for CI9H32N2O2. Found 343.2 [M+Na]+.

[0197] tert-butyl (3-(benzyl(3-hydroxypropyl)amino)propyl)carbamate (28b). 0.32 mL (2 mmol) 3-(benzylamino)propan-1-ol, 0.478 mg (2 mmol) tert-butyl (3-bromopro- pyl)carbamate, 1.3 g (4 mmol) cesium carbonate, and 0.333 g (2 mmol) potassium iodide were added in a flask with 8 mL acetone. The mixture was stirred at rt for 16 h. After com- plete reaction, the mixture was diluted with EtOAc, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The crude product was purified via flash chromatography (SiO2; DCM / MeOH + 1 % NH30 - 5 %) obtaining a colorless oil in 60 % yield (0.388 g, 1.2 mmol).1H NMR (400 MHz, CDCI3) δ 7.36 - 7.22 (m, 5H), 3.72 (t, 2H), 3.54 (s, 2H), 3.09 (q, J = 6.6 Hz, 2H), 2.63 (t, J = 5.2 Hz, 2H), 2.46 (t, J = 7.0 Hz, 2H), 1.77 - 1.64 (m, 4H), 1.46 - 1.40 (m, 11 H).13C NMR (101 MHz, CDCI3) δ 156.12, 138.44, 129.29, 128.61 ,127.44, 63.58, 59.03, 53.60, 51.45, 29.40, 28.55, 28.50, 28.33, 27.16. TLC-MS (ESI+): calcd. m / z 322.23 for Ci8H3oN203. Found 345.0 [M+Na]+. HPLC fa = 3.595 min.

[0198] tert-butyl (3-(benzyl(phenethyl)amino)propyl)carbamate (29b). 0.2 mg (0.94 mmol) 29c, 0.225 mg (0.94 mmol) tert-butyl (3-bromopropyl)carbamate, 0.616 g (1.89 mmol) cesium carbonate, and 0.157 g (0.94 mmol) potassium iodide were added in a flask with 4 mL acetone. The mixture was stirred at rt for 16 h. After complete reaction, the mixture was diluted with EtOAc, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dry- ness. The crude product was purified via flash chromatography (SiO2; DCM / MeOH 0 - 4 %) obtaining a yellow oil in 51 % yield (0.178 g, 0.48 mmol).1H NMR (400 MHz, CDCI3) δ 7.34 - 7.00 (m, 11 H), 3.56 (s, 2H), 2.81 - 2.56 (m, 4H), 2.49 (t, J = 6.4 Hz, 2H), 1.65 - 1.51 (m, 2H), 1.46 - 1.36 (m, 11H).13C NMR (101 MHz, CDCI3) δ 155.99, 140.44, 139.35, 128.88, 128.70, 128.31, 128.27, 126.98, 125.93, 58.81 , 55.49, 52.14, 39.60, 33.39, 28.49,28.44, 26.69. TLC-MS (ESI+): calcd. m / z 368.25 for C23H32N2O2. Found 369.1 [M+H]+. HPLC fa = 5.924 min.

[0199] tert-butyl (3-(benzyl(3-phenylpropyl)amino)propyl)carbamate (30b). 0.224 mg (1 mmol) 30c, 0.237 mg (1 mmol) tert-butyl (3-bromopropyl)carbamate, 0.649 g(2 mmol) cesium carbonate, and 0.165 g (1 mmol) potassium iodide were added in a flask with 4 mL acetone. The mixture was stirred at rt for 16 h. After complete reaction, the mix- ture was diluted with EtOAc, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The crude product was purified via flash chromatography (SiO?; DCM / MeOH 0 - 4 %) ob- taining a yellow oil in 48 % yield (0.184 g, 0.48 mmol).1H NMR (400 MHz, CDCI3) δ 7.36 - 7.30 (m, 4H), 7.28 - 7.12 (m, 7H), 3.54 (s, 2H), 3.16 (q, J = 6.1 Hz, 2H), 2.60 (t, J = 6.8 Hz, 2H), 2.53 - 2.40 (m, 4H), 1.86 - 1.78 (m, 2H), 1 .63 (quint, J = 6.3 Hz, 2H), 1.43 (s, 9H).13C NMR (101 MHz, CDCI3) δ 156.15, 142.41 , 139.58, 129.13, 128.72, 128.49, 128.43, 127.11 , 125.84, 78.82, 59.02, 53.55, 52.69, 40.03, 33.77, 28.94, 28.61 , 28.56, 26.63. TLC-MS (ESI+): calcd. m / z 382.26 for C24H34N2O2. Found 383.1 [M+H]+. HPLC fR= 6.308 min.

[0200] A / 1-ethyl-A / 1-(4-fluorobenzyl)propane-1 ,3-diamine dihydrochloride (32b). 0.731 g (2.35 mmol) 32c was dissolved in 11.8 mL (47.1 mmol) 4M HCI in 1 ,4-dioxane. The mixture was stirred at room temperature for 1 h. The formed product was filtered off by suction filtration and dried under reduced pressure obtaining a white semi-solid in 55 % yield (0.368 g, 1.3 mmol). The product was used without further purification. TLC-MS (ESI+): calcd. m / z 210.15 for CI2HI9FN2. Found 211.2 [M+H]+.

[0201] ferf-butyl (3-(3,4-dihydroisoquinolin-2(1 / 7)-yl)propyl)carbamate (35b). 0.26 mL (2.1 mmol) 1 ,2,3,4-tetrahydroisoquinoline, 0.5 g (2.1 mmol) terf-butyl (3-bromo- propyl)carbamate, 1 .37 g (4.2 mmol) cesium carbonate, and 0.35 g (2.1 mmol) potassium iodide were added in a flask with 8.4 mL acetone. The mixture was stirred at rt for 72 h. After complete reaction, the mixture was diluted with EtOAc, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, fil- tered, and evaporated to dryness. The mixture was purified via flash chromatography (SiO2; DCM / MeOH 0 - 3 %). The crude product was used without further purification. TLC- MS (ESI+): calcd. m / z 290.2 for C17H26N2O2. Found 313.2 [M+Na]+.

[0202] fert-butyl (3-((3-(4-fluorobenzamido)benzyl)(methyl)amino)propyl)carba- mate (36b). 0.4 g (1.65 mmol) 36c was dissolved in 15 mL THF and one drop of aceticacid was added. After 15 min of continuous stirring, 0.3 mL (1 .5 mmol) tert-butyl (3-(me- thylamino)propyl)carbamate was added and the mixture was stirred for 1 h. The mixture was cooled to 0DC and 0.476 g (2.25 mmol) sodium triacetoxyborohydride was added. Af- ter complete reaction, the mixture was diluted with EtOAc, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The crude product was used without further purification. TLC-MS (ESI+): calcd. m / z 415.23 for C23H30FN3O3. Found 438.2 [M+Na]+.

[0203] tert-butyl (3-(4-(tert-butylcarbamoyl)piperidin-1-yl)propyl)carbamate (37b). 0.3 g (1.36 mmol) 37c, 0.324 g (1.36 mmol) tert-butyl (3-bromopropyl)carbamate, 1.328 g (4.08 mmol) cesium carbonate, and 0.113 g (0.68 mmol) potassium iodide were added in a flask with 5.44 mL acetone. The mixture was stirred for 16 h at rt. After com- plete reaction, the mixture was diluted with EtOAc, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness obtaining a yellow semi-solid in 80 % yield (0.371 g, 1.09 mmol).1H NMR (400 MHz, CDCI3) δ 5.40 (s, 1 H), 5.24 (s, 1 H), 3.22 - 3.11 (m, 2H), 3.02 - 2.88 (m, J = 11.7 Hz, 2H), 2.37 (t, J = 6.7 Hz, 2H), 1 .98 - 1.77 (m, 5H), 1.73 - 1.57 (m, 4H), 1.43 (s, 9H), 1.32 (s, 9H).13C NMR (101 MHz, CDCI3) δ 174.3, 156.2, 57.1 , 53.4, 51.1 , 44.3, 40.1 , 29.3, 29.0, 28.6, 28.5, 26.7. TLC-MS (ESI+): calcd. m / z 341.27 for C18H35N3O3. Found 342.3 [M+H]+.

[0204] tert-butyl ((1-benzylpiperidin-3-yl)methyl)carbamate (39b). 0.16 mL (1 .54 mmol) benzaldehyde was dissolved in 14 mL THF, and one drop of acetic acid was added. After 15 min of continuous stirring, 0.3 g (1.4 mmol) tert-butyl (piperidin-3-ylme- thyl)carbamate was added, and the mixture was stirred for 1 h. The mixture was cooled to 0 °C and 0.445 g (2.1 mmol) sodium triacetoxyborohydride was added. After complete re- action, the mixture was diluted with EtOAc, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The crude product was purified via flash chromatography (SiO2; DCM / MeOH 0 - 7 %) obtaining a yellow oil in 39 % yield (0.165 g, 0.54 mmol).1H NMR (400 MHz, CDCI3) δ 7.54 - 7.27 (m, 5H), 4.66 (s, 1 H), 3.65 (s, 2H), 3.33 - 2.74 (m, 5H), 2.24 - 1.58 (m, 6H), 1.42 (s, 9H). TLC-MS (ESI+): calcd. m / z 304.22 for Ci8H28N2O2. Found 327.1 [M+Na]+.

[0205] tert-butyl 4-(3-(4-fluorobenzamido)benzyl)-1 ,4-diazepane-1 -carboxylate (41 b). 0.37 g (1.52 mmol) 36c was dissolved in 14 mL THF and one drop of acetic acid was added. After 15 min of continuous stirring, 0.27 mL (1.38 mmol) tert-butyl 1 ,4-diaze- pane-1 -carboxylate was added, and the mixture was stirred for 1 h. The mixture was cooled to 0 °C and 0.44 g (2.07 mmol) sodium triacetoxyborohydride was added. After complete reaction, the mixture was diluted with EtOAc, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The crude product was purified via flash chromatography (SiO?; DCM / MeOH 1 - 3 %) obtaining a yellow oil in 92 % yield (0.544 g, 1 .27 mmol).1H NMR (400 MHz, CDCI3) δ 8.30 (d, J = 61.0 Hz, 1 H), 8.01 - 7.88 (m, 2H), 7.85 - 7.65 (m, 2H), 7.33 (t, J = 7.8 Hz, 1 H), 7.14 (t, J = 8.5 Hz, 3H), 3.80 (d, J = 9.5 Hz, 2H), 3.67 - 3.52 (m, J = 20.1 Hz, 2H), 3.53 - 3.41 (m, 2H), 2.92 - 2.71 (m, J = 16.0 Hz, 4H), 2.02 - 1 .93 (m, J = 10.7, 5.5 Hz, 2H), 1.45 (s, 9H).13C NMR (101 MHz, CDCI3) δ 166.32, 165.01 , 163.81 , 155.81 , 155.46, 138.68, 131.08, 129.78, 129.46, 125.68, 121.36, 120.26, 115.99, 115.77, 80.00, 61.91 , 56.13, 54.85, 54.13, 45.58, 44.87, 28.60. TLC-MS (ESI+): calcd. m / z 427.23 for C22H32N4O2S. Found 450.2 [M+Na]+. HPLC fR= 5.309 min.

[0206] 2-(3-nitrobenzyl)isoindoline-1 , 3-dione (42b). 1 g (4.63 mmol) 1-(bromo- methyl)-3-nitrobenzene was dissolved in 14 mL DMF, and 0.943 g (5.09 mmol) phthalimide potassium salt was added in small portions. The reaction mixture was stirred for 2h at room temperature. Water was added to the mixture and the resulting suspension was filtered. The solid was washed with water multiple times and dried at 50°C under re- duced pressure obtaining a brown solid in 92 % yield (1.202 g, 4.26 mmol).1H NMR (400 MHz, DMSO) δ 8.22 - 8.17 (m, 1 H), 8.16 - 8.10 (m, 1 H), 7.96 - 7.83 (m, 4H), 7.79 (d, J = 7.7 Hz, 1 H), 7.63 (t, J = 7.9 Hz, 1 H), 4.92 (s, 2H).13C NMR (101 MHz, DMSO) δ 167.70, 147.88, 138.83, 134.60, 134.19, 131.61 , 130.17, 123.31 , 122.45, 122.34, 40.23. TLC-MS (ESI+): calcd. m / z 282.06 for C15HWN2O4. Found 305.1 [M+Na]+. HPLC fa = 7.573 min.

[0207] tert-butyl 4-(3-(1 ,3-dioxoisoindolin-2-yl)propyl)piperazine-1 -carboxylate (46b). 3 g (11.2 mmol) / V-(3-Bromopropyl)phthalimide and 2.08 g (11.2 mmol) 1-Boc-pi- perazine were dissolved in 45 mL DMF. 2.3 mL (13.4 mmol) DIPEA was added, and the mixture was heated to 100 °C for 72 h. After complete reaction, the mixture was diluted with EtOAc, washed with water (3x 30 mL) and brine (3x 30 mL). The combined organicphased were dried over Na2SO4, filtered, and evaporated to dryness obtaining a brown solid. The crude product was used without further purification. TLC-MS (ESI+): calcd. m / z 373.20 for C20H27N3O4. Found 374.2 [M+H]+.

[0208] tert-butyl 4-(benzylcarbamoyl)piperidine-1 -carboxylate (48b). 0.314 g (1.37 mmol) 37e was dissolved in 4 mL DCM and 0.573 g (1.51 mmol) HATU was slowly added. After 15 min of continuous stirring, 0.45 mL (4.11 mmol) phenylmethanamine and 0.21 mL (1 .51 mmol) triethylamine was added to the mixture. The mixture was allowed to stir at room temperature overnight. After complete reaction, the mixture was diluted with DCM, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness obtaining a brown solid. TLC- MS (ESI+): calcd. m / z 318.19 for C18H26N2O3. Found 341.2 [M+Na]+.

[0209] 1-(4-fluorophenyl)-A / -methylmethanamine (20c). 1.32 mL (2.65 mmol) 2M methanamine in THF, 0.33 mL (2.65 mmol) 1-(bromomethyl)-4-fluorobenzene, 1.72 g (5.29 mmol) cesium carbonate, and 0.22 g (1.32 mmol) potassium iodide were added in a flask with 11 mL acetone. The mixture stirred at room temperature for 72 h. After complete reaction, the formed precipitate was filtered off, the filtrate was concentrated and redis- solved in DCM. The solution was washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness obtaining a yellow oil. The crude product was used without further purification.

[0210] / V-benzyl-2-phenylethan-1 -amine (29c). 0.25 mL (2.48 mmol) benzalde- hyde was dissolved in 12 mL EtOH. After 15 min of continuous stirring, 0.31 mL (2.48 mmol) 2-phenylethan-1 -amine was added, and the mixture was stirred for 1 h. The mix- ture was cooled to 0DC and 0.311 g (4.95 mmol) sodium cyanoborohydride was added. After complete reaction, the solvent was removed under reduced pressure, and the mix- ture was diluted with water. The mixture was extracted with DCM (3x 10 mL), washed with water (3x 10 mL), and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The crude product was purified via flash chromatography (SiCfe; DCM / MeOH + 1% NH30 - 4 %) obtaining a yellow oil in 38 % yield (0.2 g, 0.94 mmol).1H NMR (400 MHz, CDCI3) δ 7.33 - 7.13 (m, 11 H), 3.76 (s, 2H), 2.91 - 2.83 (m, 2H), 2.83 - 2.75 (m, 2H).13C NMR (101 MHz, CDCI3) δ 140.40, 140.16, 128.85,128.58, 128.51 , 128.20, 127.03, 126.27, 53.99, 50.67, 36.49. TLC-MS (ESI+): calcd. m / z 211.14 for C15H17N. Found 212.0 [M+H]+. HPLC fR= 3.352 min.

[0211] / V-benzyl-3-phenylpropan-1-amine (30c). 0.23 mL (2.22 mmol) benzalde- hyde was dissolved in 11 mL EtOH. After 15 min of continuous stirring, 0.32 mL (2.22 mmol) 3-phenylpropan-1 -amine was added, and the mixture was stirred for 1 h. The mix- ture was cooled to 0 °C and 0.279 g (4.44 mmol) sodium cyanoborohydride was added. After complete reaction, the solvent was removed under reduced pressure, and the mix- ture was diluted with water. The mixture was extracted with DCM (3x 10 mL), washed with water (3x 10 mL), and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The crude product was purified via flash chromatography (SiO?; DCM / MeOH + 1% NH30 - 5 %) obtaining a yellow oil in 33 % yield (0.166 g, 0.73 mmol).1H NMR (400 MHz, CDCI3) δ 7.32 - 7.04 (m, 10H), 3.72 (s, 2H), 2.71 - 2.56 (m, 4H), 1.86 - 1.66 (m, 2H).13C NMR (101 MHz, CDCI3) δ 142.31 , 140.61 , 128.52, 128.45, 128.26, 127.03, 125.88, 54.15, 49.06, 33.77, 31.86. TLC-MS (ESI+): calcd. m / z 225.15 for CI6HI9N. Found 225.9 [M+H]+. HPLC fR= 4.126 min.

[0212] fert-butyl (3-(ethyl(4-fluorobenzyl)amino)propyl)carbamate (32c). 0.48 mL (3.15 mmol) A / -(4-fluorobenzyl)ethanamine, 0.75 g (3.15 mmol) terf-butyl (3-bromopro- pyl)carbamate, 2.05 g (6.3 mmol) cesium carbonate, and 0.26 g (1.57 mmol) potassium iodide were added in a flask with 12.6 mL acetone. The mixture was stirred at rt for 72 h. After complete reaction, the mixture was diluted with EtOAc, washed with water (3x 10 mL) and brine (3x 10 mL). The combined organic phased were dried over Na2SO4, fil- tered, and evaporated to dryness. The crude product was purified via flash chromatog- raphy (SiO2; PE / EtOAc 10 - 30%) obtaining a yellow oil in 39 % yield (0.377 g, 1 .21 mmol).1H NMR (400 MHz, CDCI3) δ 7.32 - 7.25 (m, J = 8.5, 5.7 Hz, 2H), 7.03 - 6.95 (m, 2H), 5.47 (s, 1 H), 3.49 (s, J = 14.4 Hz, 2H), 3.15 (q, J = 11.6, 5.7 Hz, 2H), 2.51 - 2.39 (m, 4H), 1.61 (quint, J = 12.6, 6.4 Hz, 2H), 1.43 (s, 9H), 1.03 (t, 3H). TLC-MS (ESI+): calcd. m / z 310.41 for C17H27FN2O2. Found 311.2 [M+H]+.

[0213] 4-fluoro-A / -(3-formylphenyl)benzamide (36c). 10% Hydrochloric acid (16 mL) was added dropwise to a stirring solution of 1.4 g (4.91 mmol) 36d in 27 mL acetone. The mixture was stirred for 30 minutes at room temperature. The solution was cooled to4°C and stirred overnight. After complete reaction, the mixture was treated with NaHCOs solution and acetone was evaporated under reduced pressure. The remaining solid was filtered by suction filtration and washed multiple times with water. The solid product was dried under reduced pressure obtaining a white solid in 68 % yield (0.812 g, 3.34 mmol).1H N MR (400 MHz, CDCI3) δ 9.98 (s, 1 H), 8.29 (s, 1 H), 8.12 (d, J = 1.6 Hz, 1 H), 8.03 (td, J = 8.2, 2.3 Hz, 1 H), 7.96 - 7.88 (m, 2H), 7.64 (t, J = 8.8 Hz, 1 H), 7.56 - 7.48 (m, 1 H), 7.19 - 7.11 (m, 2H).13C NMR (101 MHz, CDCI3) δ 192.2, 166.5, 165.1 , 164.0, 139.0, 137.2, 130.0, 129.8, 129.7, 126.3, 126.2, 120.9, 116.2, 116.0. TLC-MS (ESI+): calcd. m / z 243.07 for C14H10FNO2. Found 266.2 [M+Na]+.

[0214] A / -(ferf-butyl)piperidine-4-carboxamide hydrochloride (37c). 1.47 g (5.17 mmol) 37d was dissolved in 26 ml_ (104 mmol) 4M HCI in 1 ,4-dioxane. The mixture was stirred at room temperature for 3 h. The formed product was filtered off by suction filtration and dried under reduced pressure obtaining a white solid in 89 % yield (1.015 g, 4.6 mmol). The product was used without further purification.

[0215] A / -(3-(1 ,3-dioxolan-2-yl)phenyl)-4-fluorobenzamide (36d). 0.9 g (6.42 mmol) 4-fluorobenzoic acid was dissolved in 26 ml_ dry DMF and 2.69 g (7.07 mmol) HATU was slowly added. After 15 min of continuous stirring, 1.06 g (6.42 mmol) 3-(1 ,3- dioxolan-2-yl)aniline and 2.8 mL (16.06 mmol) DIPEA was added to the mixture. The mix- ture was allowed to stir at room temperature overnight. After complete reaction, the mix- ture was diluted with DCM, washed with water (3x 20 mL) and brine (3x 20 mL). The com- bined organic phased were dried over Na2SO4, filtered, and evaporated to dryness. The crude product was purified via flash chromatography (SiO2; PE / EtOAc 0 - 30 %) obtaining a white solid in 76 % yield (1.4 g, 4.88 mmol).1H NMR (400 MHz, DMSO) δ 10.32 (s, 1 H), 8.08 - 8.02 (m, 2H), 7.87 (t, J = 1.7 Hz, 1 H), 7.81 - 7.77 (m, J = 12.2, 4.0, 3.0 Hz, 1 H), 7.39 - 7.34 (m, J = 12.4, 5.2 Hz, 3H), 7.17 (d, J = 7.6 Hz, 1 H), 5.73 (s, 1 H), 4.09 - 3.91 (m, 4H).13C NMR (101 MHz, DMSO) δ 164.5, 139.1, 138.7, 130.5, 130.4, 128.5, 122.0, 121.0, 118.5, 115.5, 115.3, 102.7, 64.8. TLC-MS (ESI+): calcd. m / z 287.10 for CI6HI4FNO3. Found 310.1 [M+Na]+.

[0216] fert-butyl 4-(tert-butylcarbamoyl)piperidine-1 -carboxylate (37d). 1.23 g (5.36 mmol) 37e was dissolved in 16 mL DCM and 2.24 g (5.9 mmol) HATU was slowlyadded. After 15 min of continuous stirring, 1.7 mL (16.1 mmol) ferf-Butylamine and 0.82 mL (5.9 mmol) triethylamine was added to the mixture. The mixture was allowed to stir at room temperature overnight. After complete reaction, the mixture was diluted with DCM, washed with water (3x 20 mL) and brine (3x 20 mL). The combined organic phased were dried over Na2SO4, filtered, and evaporated to dryness obtaining a white solid in 97 % yield (1.48 g, 5.2 mmol).1H NMR (400 MHz, DMSO) δ 7.35 (s, 1 H), 3.93 (d, J = 12.1 Hz, 2H), 2.77 - 2.61 (m, J = 9.2 Hz, 2H), 2.23 (tt, J = 11.5, 3.6 Hz, 1 H), 1.62 - 1 .53 (m, J = 12.8, 2.2 Hz, 2H), 1.39 (s, 9H), 1.37 - 1.30 (m, 2H), 1.22 (s, 9H).13C NMR (101 MHz, DMSO) δ 173.6, 153.8, 78.5, 49.7, 42.1, 38.2, 28.5, 28.3, 28.1. TLC-MS (ESI+): calcd. m / z 284.21 for C15H28N2O3. Found 307.2 [M+Na]+.

[0217] 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (37e). 1 g (3.9 mmol) 1 -(ferf-butyl) 4-ethyl piperidine-1,4-dicarboxylate was stirred with 29 mL (29.15 mmol) 1M aqueous NaOH solution at room temperature for 16 h. After complete reaction, the mix- ture was acidified, and the precipitate was collected by suction filtration obtaining a white solid in 82 % yield (0.731 g, 3.19 mmol).1H NMR (400 MHz, DMSO) δ 12.25 (s, 1H), 3.83 (d, J = 13.1 Hz, 2H), 2.81 (s, 2H), 2.39 (tt, J = 11.0, 3.8 Hz, 1H), 1.77 (dd, J = 13.3, 3.2 Hz, 2H), 1.44 - 1.31 (m, 11 H).13C NMR (101 MHz, DMSO) δ 175.7, 153.9, 78.6, 42.7, 40.1, 28.1, 27.8. TLC-MS (ESI-): calcd. m / z 229.13 for C11H19NO4. Found 228.1 [M-H] .

Claims

Claims1 . A compound of any of the general formulas (la) to (Ig):or a stereoisomer, enantiomer, tautomer, pro-drug and / or a pharmaceutically ac- ceptable salt thereof, whereinX1is selected from substituted or unsubstituted cyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted fused cyclyl, and substituted or unsubstituted fused heterocyclyl,X2is selected from -SCH2-, -CH2CH2-, and a bond,X3is selected from carbonyl, thiocarbonyl, and methylene,Y1is selected from H and methyl,Y2is selected from substituted or unsubstituted phenyl, substituted or unsubsti- tuted benzyl, fert-butyl and tert-butyloxycarbonyl,Y3is selected from H, substituted or unsubstituted C1-C5 alkyl, and C3-C5 cycloal- kyl,Y4and Y5are O, or Y4is selected from H, and methyl, Y5is selected from substi- tuted or unsubstituted benzyl, substituted or unsubstituted benzoyl, and linear or branched C1-C5 alkyl carboxyl ate,A and B are independently selected from substituted or unsubstituted heterocyclyl, and substituted or unsubstituted fused heterocyclyl,C is selected from substituted or unsubstituted cyclyl, and n is 0-2.

2. The compound of claim 1 , wherein the compound has the formula (la) or (lb), whereinX1is substituted or unsubstituted heterocyclyl, preferably substituted or unsubsti- tuted thiophen-2-yl, more preferably, (substituted or unsubstituted phenyl)thiophen-2-yl,X2is a bond,X3is carbonyl,Y1is HY2is unsubstituted benzyl,Y3is selected from linear or branched C1-C4 alkyl, C2-C3 alkyl phenyl and C3-C4 cy- cloalkyl, preferably methyl, andA is selected from substituted or unsubstituted 1 -piperidinyl, substituted or unsub- stituted 1-(2,3,4-triyhydro)chinoline, and substituted or unsubstituted 1-(2,3-dihydro)indole, and n is 1 .

3. The compound according to any of the preceding claims, wherein the compound has any of the general formulas (Ila) to (He):R4is H or halogen, preferably F.

4. The compound according to any of the preceding claims, wherein the compound has the general formula (lid) or (He):

5. The compound according to any of the preceding claims, wherein the compound has a [3-Arrestin recruitment ECso of 0.5 pM or less, preferably 0.1 pM or less, and / or a P- Selectin expression reduction of 71 % or more, preferably 90% or more.

6. A pharmaceutical composition comprising the compound of any one of claims 1 to 5 or a pharmaceutically acceptable salt, pro-drug, biologically active metabolite, solvate or stereoisomer thereof.

7. The pharmaceutical composition according to claim 6, further comprising an inert carrier and / or one or more other therapeutic agents.

8. A compound of any one of claims 1 to 5 or a pharmaceutically acceptable salt, pro- drug, biologically active metabolite, solvate or stereoisomer thereof, or the composition of claim 6 or 7, for use in the treatment of a disease or disorder.

9. The compound or the composition of claim 8, wherein the disease is mediated by ACKR3.

10. The compound or the composition of claim 8 or 9, wherein the disease or disorder is selected from the group consisting of pain, distress dysfunction diseases or conditions, cancers, inflammatory or autoimmune diseases and conditions, conditions of excessive or abnormal vascularization (including wound healing and HIV infectivity), stem cell differenti- ation and mobilization disorders, brain and neuronal dysfunctions (including Alzheimer's disease, multiple sclerosis and demyelinating diseases), kidney dysfunction, renal dys- function, preeclampsia and obesity in a subject.11 . The compound or the composition of any of claims 8 to 10, wherein the disease is a cardiovascular disease or a platet disorder, preferably the cardiovascular disease is se- lected from coronary artery diseases, such as angina pectoris and heart attack, stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, ab- normal heart rhythms, congenital heart disease, valvular heart disease, carditis, aortic an- eurysms, peripheral artery disease, thromboembolic disease, venous thrombosis, and ath- erosclerosis and wherein the platelet disorder is selected from thrombocytosis, thrombo- cythemia, and thrombocytopenia, such as immune thrombocytopenia and thrombotic thrombocytopenic purpura, Bernard Soulier disease, Glanzmann’s thrombasthenia, Her- mansky Pudlak syndrome, Jacobsen syndrome, Lowe syndrome, platelet release and storage pool defects, thrombocytopenia with absent radius (TAR) syndrome and throm- botic thrombocytopenic purpura (TTP).

12. A method for treating a disease in which mediation, such as activation or inhibition, regulation and modulation, of ACKR3 is beneficial in a human or a warm-blooded or mam- mal animal in need of such treatment, which comprises administering to said human or warm-blooded or mammal animal a therapeutically effective amount of the compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt, pro-drug, biologically ac- tive metabolite, solvate or stereoisomer thereof, or the composition of claim 6 or 7.

13. The method of claim 12, wherein the disease is a cardiovascular disease or a platelet disorder.

14. The method of claim 13, wherein the cardiovascular disease is selected from coro- nary artery diseases, such as angina pectoris and heart attack, stroke, heart failure, hy- pertensive heart disease, rheumatic heart disease, cardiomyopathy, abnormal heart rhythms, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, pe- ripheral artery disease, thromboembolic disease, venous thrombosis, and atherosclerosis and wherein the platelet disorder is selected from thrombocytosis, thrombocythemia, and thrombocytopenia, such as immune thrombocytopenia and thrombotic thrombocytopenic purpura, Bernard Soulier disease, Glanzmann’s thrombasthenia, Hermansky Pudlak syn- drome, Jacobsen syndrome, Lowe syndrome, platelet release and storage pool defects, thrombocytopenia with absent radius (TAR) syndrome and thrombotic thrombocytopenic purpura (TTP).

15. The method of claim 12, wherein the disease is selected from the group consisting of: distress dysfunction diseases or conditions, chronic or acute pain, cancers (incl. breast, brain, lymphoma), fibrosis (incl. cardiac fibrosis), inflammatory or autoimmune dis- eases and conditions, conditions of excessive or abnormal vascularization (incl. wound healing), stem cell differentiation and mobilization disorders, brain and neuronal dysfunc- tions (incl. Alzheimer's disease, multiple sclerosis and demyelinating diseases), kidney dysfunction, renal dysfunction, preeclampsia and obesity.

Images